AU2004253929A1 - Sulfonamide substituted imidazoquinolines - Google Patents
Sulfonamide substituted imidazoquinolines Download PDFInfo
- Publication number
- AU2004253929A1 AU2004253929A1 AU2004253929A AU2004253929A AU2004253929A1 AU 2004253929 A1 AU2004253929 A1 AU 2004253929A1 AU 2004253929 A AU2004253929 A AU 2004253929A AU 2004253929 A AU2004253929 A AU 2004253929A AU 2004253929 A1 AU2004253929 A1 AU 2004253929A1
- Authority
- AU
- Australia
- Prior art keywords
- imidazo
- quinolin
- amino
- butyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940124530 sulfonamide Drugs 0.000 title description 8
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 title description 7
- 125000000565 sulfonamide group Chemical group 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 82
- 102000004127 Cytokines Human genes 0.000 claims description 27
- 108090000695 Cytokines Proteins 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 7
- 230000001613 neoplastic effect Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- NVNWHRIYBUUBAJ-UHFFFAOYSA-N n-[1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-yl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)NS(C)(=O)=O)C3=C(N)N=C21 NVNWHRIYBUUBAJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 86
- 229910052799 carbon Inorganic materials 0.000 description 78
- 229910052757 nitrogen Inorganic materials 0.000 description 73
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- 238000006243 chemical reaction Methods 0.000 description 70
- 239000007787 solid Substances 0.000 description 55
- 239000000243 solution Substances 0.000 description 48
- 238000007429 general method Methods 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- 238000004458 analytical method Methods 0.000 description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- 239000011541 reaction mixture Substances 0.000 description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 239000000463 material Substances 0.000 description 20
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- -1 Compounds Imidazoquinolines Chemical class 0.000 description 15
- 125000000623 heterocyclic group Chemical group 0.000 description 15
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 14
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 13
- 102100040247 Tumor necrosis factor Human genes 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 13
- HQBUPOAKJGJGCD-UHFFFAOYSA-N 3h-imidazo[4,5-c]quinolin-4-amine Chemical class NC1=NC2=CC=CC=C2C2=C1N=CN2 HQBUPOAKJGJGCD-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 11
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 125000004103 aminoalkyl group Chemical group 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 150000001204 N-oxides Chemical class 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 239000006260 foam Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- GCGNWZMOENODOJ-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-imidazo[4,5-h]quinoline Chemical class C1C=C2C=CC=NC2=C2C1NCN2 GCGNWZMOENODOJ-UHFFFAOYSA-N 0.000 description 6
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000012948 isocyanate Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 150000003456 sulfonamides Chemical group 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 150000008064 anhydrides Chemical class 0.000 description 5
- 239000012442 inert solvent Substances 0.000 description 5
- 150000002513 isocyanates Chemical class 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- ITIRVXDSMXFTPW-UHFFFAOYSA-N 1H-imidazo[4,5-c]quinoline Chemical group C1=CC=CC2=C(NC=N3)C3=CN=C21 ITIRVXDSMXFTPW-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- KZWUQTRMSBGBBN-UHFFFAOYSA-N 1-(3-aminopropyl)-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(CCOC)=N3)CCCN)C3=C(N)N=C21 KZWUQTRMSBGBBN-UHFFFAOYSA-N 0.000 description 3
- ZPJBFQVJSMEECU-UHFFFAOYSA-N 2-butyl-1-[4-(1,1-dioxo-1,2-thiazolidin-2-yl)butyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCCN1CCCS1(=O)=O ZPJBFQVJSMEECU-UHFFFAOYSA-N 0.000 description 3
- XYYKPSXKBVBMHJ-UHFFFAOYSA-N 3-(2-butylimidazo[4,5-c]quinolin-1-yl)propan-1-amine Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCCN)C3=CN=C21 XYYKPSXKBVBMHJ-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 229910004298 SiO 2 Inorganic materials 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 229940124669 imidazoquinoline Drugs 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- VQDBDUUBRYJICF-UHFFFAOYSA-N n-[2-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)ethyl]-4-methylbenzenesulfonamide Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCNS(=O)(=O)C1=CC=C(C)C=C1 VQDBDUUBRYJICF-UHFFFAOYSA-N 0.000 description 3
- ZGEPNYAAUQVVLM-UHFFFAOYSA-N n-[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl]benzenesulfonamide Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCNS(=O)(=O)C1=CC=CC=C1 ZGEPNYAAUQVVLM-UHFFFAOYSA-N 0.000 description 3
- XKWXZYMYHSFUJW-UHFFFAOYSA-N n-[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl]-4-methylbenzenesulfonamide Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCNS(=O)(=O)C1=CC=C(C)C=C1 XKWXZYMYHSFUJW-UHFFFAOYSA-N 0.000 description 3
- YODWHKFJJPXAQD-UHFFFAOYSA-N n-[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl]benzenesulfonamide Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCNS(=O)(=O)C1=CC=CC=C1 YODWHKFJJPXAQD-UHFFFAOYSA-N 0.000 description 3
- FRXDVFQORNBEFL-UHFFFAOYSA-N n-[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CCOC)=N3)CCCNS(C)(=O)=O)C3=C(N)N=C21 FRXDVFQORNBEFL-UHFFFAOYSA-N 0.000 description 3
- OCGIGXADEWZZPL-UHFFFAOYSA-N n-[3-[4-amino-2-(3-phenoxypropyl)imidazo[4,5-c]quinolin-1-yl]propyl]methanesulfonamide Chemical compound N=1C2=C(N)N=C3C=CC=CC3=C2N(CCCNS(=O)(=O)C)C=1CCCOC1=CC=CC=C1 OCGIGXADEWZZPL-UHFFFAOYSA-N 0.000 description 3
- FDURDVQGNXYXGG-UHFFFAOYSA-N n-[3-[4-amino-2-(ethoxymethyl)-6,7,8,9-tetrahydroimidazo[4,5-c]quinolin-1-yl]propyl]methanesulfonamide Chemical compound C1CCCC2=C(N(C(COCC)=N3)CCCNS(C)(=O)=O)C3=C(N)N=C21 FDURDVQGNXYXGG-UHFFFAOYSA-N 0.000 description 3
- XHFIIYXNIHVLAV-UHFFFAOYSA-N n-[4-(2-hexylimidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide Chemical compound CCCCCCC1=NC2=CN=C3C=CC=CC3=C2N1CCCCNS(=O)(=O)C1=CC=CC=C1 XHFIIYXNIHVLAV-UHFFFAOYSA-N 0.000 description 3
- YZOQZEXYFLXNKA-UHFFFAOYSA-N n-[4-(4-amino-2-ethylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CC)=N3)CCCCNS(C)(=O)=O)C3=C(N)N=C21 YZOQZEXYFLXNKA-UHFFFAOYSA-N 0.000 description 3
- TWEWOQRUFLEQNL-UHFFFAOYSA-N n-[4-(4-amino-2-hexylimidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide Chemical compound CCCCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCCNS(=O)(=O)C1=CC=CC=C1 TWEWOQRUFLEQNL-UHFFFAOYSA-N 0.000 description 3
- ZUFWEBGOLJHBJM-UHFFFAOYSA-N n-[4-(4-amino-2-hexylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CCCCCC)=N3)CCCCNS(C)(=O)=O)C3=C(N)N=C21 ZUFWEBGOLJHBJM-UHFFFAOYSA-N 0.000 description 3
- CCJISYWPWXKKRX-UHFFFAOYSA-N n-[4-(4-amino-2-methylimidazo[4,5-c]quinolin-1-yl)butyl]ethanesulfonamide Chemical compound C1=CC=CC2=C3N(CCCCNS(=O)(=O)CC)C(C)=NC3=C(N)N=C21 CCJISYWPWXKKRX-UHFFFAOYSA-N 0.000 description 3
- DOZGTYGEBVOOFZ-UHFFFAOYSA-N n-[4-(4-amino-2-methylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(C)=N3)CCCCNS(C)(=O)=O)C3=C(N)N=C21 DOZGTYGEBVOOFZ-UHFFFAOYSA-N 0.000 description 3
- GYAGKIRWXLWSHY-UHFFFAOYSA-N n-[4-(4-amino-2-pentylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CCCCC)=N3)CCCCNS(C)(=O)=O)C3=C(N)N=C21 GYAGKIRWXLWSHY-UHFFFAOYSA-N 0.000 description 3
- KCQWOAPKZGATTP-UHFFFAOYSA-N n-[4-(4-amino-2-propylimidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide Chemical compound CCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCCNS(=O)(=O)C1=CC=CC=C1 KCQWOAPKZGATTP-UHFFFAOYSA-N 0.000 description 3
- KSQUPKPKVHSLDC-UHFFFAOYSA-N n-[4-(4-amino-2-propylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CCC)=N3)CCCCNS(C)(=O)=O)C3=C(N)N=C21 KSQUPKPKVHSLDC-UHFFFAOYSA-N 0.000 description 3
- ZOCPCRFSEJMATG-UHFFFAOYSA-N n-[8-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]octyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CCOC)=N3)CCCCCCCCNS(C)(=O)=O)C3=C(N)N=C21 ZOCPCRFSEJMATG-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- SVBZCXQPNPURIX-UHFFFAOYSA-N 1-(2-amino-2-methylpropyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)N)C3=C(N)N=C21 SVBZCXQPNPURIX-UHFFFAOYSA-N 0.000 description 2
- KRQJNCKJBILJJJ-UHFFFAOYSA-N 1-(3-aminopropyl)-2-butylimidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCCN)C3=C(N)N=C21 KRQJNCKJBILJJJ-UHFFFAOYSA-N 0.000 description 2
- GHDRXJRPAIWZSQ-UHFFFAOYSA-N 1-(4-aminobutyl)-2-methylimidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(C)=N3)CCCCN)C3=C(N)N=C21 GHDRXJRPAIWZSQ-UHFFFAOYSA-N 0.000 description 2
- OCBWXUGUCGMZBA-UHFFFAOYSA-N 1-(4-aminobutyl)-2-pentylimidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(CCCCC)=N3)CCCCN)C3=C(N)N=C21 OCBWXUGUCGMZBA-UHFFFAOYSA-N 0.000 description 2
- JUWNVLFAZIWTMU-UHFFFAOYSA-N 1-(8-aminooctyl)-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(CCOC)=N3)CCCCCCCCN)C3=C(N)N=C21 JUWNVLFAZIWTMU-UHFFFAOYSA-N 0.000 description 2
- CRHYJWBCRXKHRN-UHFFFAOYSA-N 1-[4-(1,1-dioxo-1,2-thiazolidin-2-yl)butyl]-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCCN1CCCS1(=O)=O CRHYJWBCRXKHRN-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- GPKDGVXBXQTHRY-UHFFFAOYSA-N 3-chloropropane-1-sulfonyl chloride Chemical compound ClCCCS(Cl)(=O)=O GPKDGVXBXQTHRY-UHFFFAOYSA-N 0.000 description 2
- LTPVCZQGBDHLMG-UHFFFAOYSA-N 4-(2-ethylimidazo[4,5-c]quinolin-1-yl)butan-1-amine Chemical compound C1=CC=CC2=C(N(C(CC)=N3)CCCCN)C3=CN=C21 LTPVCZQGBDHLMG-UHFFFAOYSA-N 0.000 description 2
- BHBQPNUVSWIHOD-UHFFFAOYSA-N 4-(2-hexylimidazo[4,5-c]quinolin-1-yl)butan-1-amine Chemical compound C1=CC=CC2=C(N(C(CCCCCC)=N3)CCCCN)C3=CN=C21 BHBQPNUVSWIHOD-UHFFFAOYSA-N 0.000 description 2
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 description 2
- ZRFUZDDJSQVQBY-UHFFFAOYSA-N 4-chloro-3-nitroquinoline Chemical compound C1=CC=CC2=C(Cl)C([N+](=O)[O-])=CN=C21 ZRFUZDDJSQVQBY-UHFFFAOYSA-N 0.000 description 2
- YHQPYMQQMBVULM-UHFFFAOYSA-N 6,7,8,9-tetrahydro-3h-imidazo[4,5-c]quinolin-4-amine Chemical class C1CCCC2=C1N=C(N)C1=C2NC=N1 YHQPYMQQMBVULM-UHFFFAOYSA-N 0.000 description 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000000051 modifying effect Effects 0.000 description 2
- XCXOKNJKBTXVOO-UHFFFAOYSA-N n-[2-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)ethyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCNS(C)(=O)=O)C3=C(N)N=C21 XCXOKNJKBTXVOO-UHFFFAOYSA-N 0.000 description 2
- CFAXOSMOLWQBGF-UHFFFAOYSA-N n-[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl]-4-methylbenzenesulfonamide Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCNS(=O)(=O)C1=CC=C(C)C=C1 CFAXOSMOLWQBGF-UHFFFAOYSA-N 0.000 description 2
- NAKYGPHKOSYEKG-UHFFFAOYSA-N n-[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl]-5-(dimethylamino)naphthalene-1-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)NCCCN3C4=C5C=CC=CC5=NC(N)=C4N=C3CCCC)=CC=CC2=C1N(C)C NAKYGPHKOSYEKG-UHFFFAOYSA-N 0.000 description 2
- MZXTVCBMZQDXTJ-UHFFFAOYSA-N n-[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)propyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCCNS(C)(=O)=O)C3=C(N)N=C21 MZXTVCBMZQDXTJ-UHFFFAOYSA-N 0.000 description 2
- GUWKXTZVCYGDQL-UHFFFAOYSA-N n-[3-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]propyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CCCNS(C)(=O)=O)C3=C(N)N=C21 GUWKXTZVCYGDQL-UHFFFAOYSA-N 0.000 description 2
- MHKJUVWISSLCEC-UHFFFAOYSA-N n-[4-(2-hexylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CCCCCC)=N3)CCCCNS(C)(=O)=O)C3=CN=C21 MHKJUVWISSLCEC-UHFFFAOYSA-N 0.000 description 2
- BKSGGCIFTFXQAH-UHFFFAOYSA-N n-[4-(4-amino-2-ethylimidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide Chemical compound CCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCCNS(=O)(=O)C1=CC=CC=C1 BKSGGCIFTFXQAH-UHFFFAOYSA-N 0.000 description 2
- HBPLVGFQUJGBPG-UHFFFAOYSA-N n-[4-(4-amino-2-methyl-6,7,8,9-tetrahydroimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide;hydrochloride Chemical compound Cl.C1CCCC2=C(N(C(C)=N3)CCCCNS(C)(=O)=O)C3=C(N)N=C21 HBPLVGFQUJGBPG-UHFFFAOYSA-N 0.000 description 2
- WMJJJJKGVPSSSN-UHFFFAOYSA-N n-[4-(4-amino-2-methylimidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide Chemical compound CC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCCNS(=O)(=O)C1=CC=CC=C1 WMJJJJKGVPSSSN-UHFFFAOYSA-N 0.000 description 2
- ASKWICZHWUUNCD-UHFFFAOYSA-N n-[4-(4-amino-2-pentyl-6,7,8,9-tetrahydroimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide Chemical compound C1CCCC2=C(N(C(CCCCC)=N3)CCCCNS(C)(=O)=O)C3=C(N)N=C21 ASKWICZHWUUNCD-UHFFFAOYSA-N 0.000 description 2
- TWCMRMWDBFPHTQ-UHFFFAOYSA-N n-[4-(4-amino-2-pentylimidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide Chemical compound CCCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCCNS(=O)(=O)C1=CC=CC=C1 TWCMRMWDBFPHTQ-UHFFFAOYSA-N 0.000 description 2
- IOHFRCYGKLBIJH-UHFFFAOYSA-N n-[4-[4-amino-2-(3-phenoxypropyl)imidazo[4,5-c]quinolin-1-yl]butyl]methanesulfonamide Chemical compound N=1C2=C(N)N=C3C=CC=CC3=C2N(CCCCNS(=O)(=O)C)C=1CCCOC1=CC=CC=C1 IOHFRCYGKLBIJH-UHFFFAOYSA-N 0.000 description 2
- NIXWJLVPEUCHEH-UHFFFAOYSA-N n-[8-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)octyl]benzenesulfonamide Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCCCCCCNS(=O)(=O)C1=CC=CC=C1 NIXWJLVPEUCHEH-UHFFFAOYSA-N 0.000 description 2
- OEWIOBQTRKZSJO-UHFFFAOYSA-N n-[8-(4-aminoimidazo[4,5-c]quinolin-1-yl)octyl]methanesulfonamide Chemical compound C1=CC=CC2=C3N(CCCCCCCCNS(=O)(=O)C)C=NC3=C(N)N=C21 OEWIOBQTRKZSJO-UHFFFAOYSA-N 0.000 description 2
- DWLBGOWKIPBKHE-UHFFFAOYSA-N n-[8-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]octyl]benzenesulfonamide Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCCCCCCNS(=O)(=O)C1=CC=CC=C1 DWLBGOWKIPBKHE-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000013014 purified material Substances 0.000 description 2
- UTOMICFLROGMAE-UHFFFAOYSA-N quinoline-3,4-diamine Chemical compound C1=CC=CC2=C(N)C(N)=CN=C21 UTOMICFLROGMAE-UHFFFAOYSA-N 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 2
- GRBPJBQMZFHFJK-UHFFFAOYSA-N tert-butyl n-[2-methyl-1-[(3-nitroquinolin-4-yl)amino]propan-2-yl]carbamate Chemical compound C1=CC=C2C(NCC(C)(C)NC(=O)OC(C)(C)C)=C([N+]([O-])=O)C=NC2=C1 GRBPJBQMZFHFJK-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- OPCJOXGBLDJWRM-UHFFFAOYSA-N 1,2-diamino-2-methylpropane Chemical compound CC(C)(N)CN OPCJOXGBLDJWRM-UHFFFAOYSA-N 0.000 description 1
- YETCZFGQAKYIEX-UHFFFAOYSA-N 1-(2-aminoethyl)-2-butylimidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCN)C3=C(N)N=C21 YETCZFGQAKYIEX-UHFFFAOYSA-N 0.000 description 1
- SVYFQELIXIKCJL-UHFFFAOYSA-N 1-(3-amino-2,2-dimethylpropyl)-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(CCOC)=N3)CC(C)(C)CN)C3=C(N)N=C21 SVYFQELIXIKCJL-UHFFFAOYSA-N 0.000 description 1
- WEDAMQZTNRHKAK-UHFFFAOYSA-N 1-(3-aminobutyl)-2-(3-phenoxypropyl)imidazo[4,5-c]quinolin-4-amine Chemical compound N=1C2=C(N)N=C3C=CC=CC3=C2N(CCC(N)C)C=1CCCOC1=CC=CC=C1 WEDAMQZTNRHKAK-UHFFFAOYSA-N 0.000 description 1
- MTROHLWKMKQWOD-UHFFFAOYSA-N 1-(3-aminopropyl)-2-(2-methoxyethyl)-6,7,8,9-tetrahydroimidazo[4,5-c]quinolin-4-amine Chemical compound C1CCCC2=C(N(C(CCOC)=N3)CCCN)C3=C(N)N=C21 MTROHLWKMKQWOD-UHFFFAOYSA-N 0.000 description 1
- JKRBRSVKGRXTJM-UHFFFAOYSA-N 1-(3-aminopropyl)-2-(3-phenoxypropyl)imidazo[4,5-c]quinolin-4-amine Chemical compound N=1C2=C(N)N=C3C=CC=CC3=C2N(CCCN)C=1CCCOC1=CC=CC=C1 JKRBRSVKGRXTJM-UHFFFAOYSA-N 0.000 description 1
- RYYIXBUGTMXUKX-UHFFFAOYSA-N 1-(3-aminopropyl)-2-(ethoxymethyl)-6,7,8,9-tetrahydroimidazo[4,5-c]quinolin-4-amine Chemical compound C1CCCC2=C(N(C(COCC)=N3)CCCN)C3=C(N)N=C21 RYYIXBUGTMXUKX-UHFFFAOYSA-N 0.000 description 1
- HVJUMTMMTHTXOF-UHFFFAOYSA-N 1-(3-aminopropyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CCCN)C3=C(N)N=C21 HVJUMTMMTHTXOF-UHFFFAOYSA-N 0.000 description 1
- OWLKVZSZMXWHTL-UHFFFAOYSA-N 1-(4-aminobutyl)-2-(cyclopropylmethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound N=1C2=C(N)N=C3C=CC=CC3=C2N(CCCCN)C=1CC1CC1 OWLKVZSZMXWHTL-UHFFFAOYSA-N 0.000 description 1
- DJILPZGMLMGVDD-UHFFFAOYSA-N 1-(4-aminobutyl)-2-ethylimidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(CC)=N3)CCCCN)C3=C(N)N=C21 DJILPZGMLMGVDD-UHFFFAOYSA-N 0.000 description 1
- QDRPAMSKNPUKMS-UHFFFAOYSA-N 1-(4-aminobutyl)-2-methyl-6,7,8,9-tetrahydroimidazo[4,5-c]quinolin-4-amine Chemical compound C1CCCC2=C(N(C(C)=N3)CCCCN)C3=C(N)N=C21 QDRPAMSKNPUKMS-UHFFFAOYSA-N 0.000 description 1
- HDDNSPWJCZZICL-UHFFFAOYSA-N 1-(6-methoxyquinolin-8-yl)-2-methylimidazo[4,5-c]quinoline Chemical compound N1=CC=CC2=CC(OC)=CC(N3C4=C5C=CC=CC5=NC=C4N=C3C)=C21 HDDNSPWJCZZICL-UHFFFAOYSA-N 0.000 description 1
- GQFYPRWOJHWGIV-UHFFFAOYSA-N 1-(8-aminooctyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C3N(CCCCCCCCN)C=NC3=C(N)N=C21 GQFYPRWOJHWGIV-UHFFFAOYSA-N 0.000 description 1
- URMAKSLECABUCE-UHFFFAOYSA-N 1-(sulfamoylamino)imidazo[4,5-c]quinoline Chemical compound C1=CC=CC2=C3N(NS(=O)(=O)N)C=NC3=CN=C21 URMAKSLECABUCE-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- GRNOZCCBOFGDCL-UHFFFAOYSA-N 2,2,2-trichloroacetyl isocyanate Chemical compound ClC(Cl)(Cl)C(=O)N=C=O GRNOZCCBOFGDCL-UHFFFAOYSA-N 0.000 description 1
- JIVYZWLGEJABCN-UHFFFAOYSA-N 2,3,3a,4-tetrahydroimidazo[4,5-c]quinolin-1-yl n-tert-butylcarbamate Chemical class C1=CC=CC2=C3N(OC(=O)NC(C)(C)C)CNC3CN=C21 JIVYZWLGEJABCN-UHFFFAOYSA-N 0.000 description 1
- ZPMWWAIBJJFPPQ-UHFFFAOYSA-N 2-ethoxyacetyl chloride Chemical compound CCOCC(Cl)=O ZPMWWAIBJJFPPQ-UHFFFAOYSA-N 0.000 description 1
- ZIGLQRLQAHWZFW-UHFFFAOYSA-N 2-methyl-2-n-(3-nitroquinolin-4-yl)propane-1,2-diamine Chemical compound C1=CC=C2C(NC(C)(CN)C)=C([N+]([O-])=O)C=NC2=C1 ZIGLQRLQAHWZFW-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- DDMGMIAKUHXOMT-UHFFFAOYSA-N 2-nitroquinolin-4-amine Chemical compound C1=CC=C2C(N)=CC([N+]([O-])=O)=NC2=C1 DDMGMIAKUHXOMT-UHFFFAOYSA-N 0.000 description 1
- PDJXJKGLLBUYFS-UHFFFAOYSA-N 3-(2-butylimidazo[4,5-c]quinolin-1-yl)propan-1-amine;hydrochloride Chemical compound Cl.C1=CC=CC2=C(N(C(CCCC)=N3)CCCN)C3=CN=C21 PDJXJKGLLBUYFS-UHFFFAOYSA-N 0.000 description 1
- GGYMUGZZJUVLGZ-UHFFFAOYSA-N 3-N-(3-nitroquinolin-4-yl)butane-2,3-diamine Chemical compound CC(C(C)N)NC1=C(C=NC2=CC=CC=C12)[N+](=O)[O-] GGYMUGZZJUVLGZ-UHFFFAOYSA-N 0.000 description 1
- SKPRPEJLFKCOAB-UHFFFAOYSA-N 3-nitroquinolin-4-amine Chemical compound C1=CC=C2C(N)=C([N+]([O-])=O)C=NC2=C1 SKPRPEJLFKCOAB-UHFFFAOYSA-N 0.000 description 1
- NOQQJBPCVDHYHY-UHFFFAOYSA-N 4-(2-butylimidazo[4,5-c]quinolin-1-yl)butane-1-sulfonamide Chemical compound C(CCC)C=1N(C2=C(C=NC=3C=CC=CC23)N1)CCCCS(=O)(=O)N NOQQJBPCVDHYHY-UHFFFAOYSA-N 0.000 description 1
- HKHKLZGFYFCZFA-UHFFFAOYSA-N 4-(2-propylimidazo[4,5-c]quinolin-1-yl)butan-1-amine Chemical compound C1=CC=CC2=C(N(C(CCC)=N3)CCCCN)C3=CN=C21 HKHKLZGFYFCZFA-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000019337 Bowen disease of the skin Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 208000006081 Cryptococcal meningitis Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 241000250507 Gigaspora candida Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010073245 Meningitis aspergillus Diseases 0.000 description 1
- 206010027209 Meningitis cryptococcal Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 240000006413 Prunus persica var. persica Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- LURYMYITPCOQAU-UHFFFAOYSA-N benzoyl isocyanate Chemical compound O=C=NC(=O)C1=CC=CC=C1 LURYMYITPCOQAU-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 206010006060 bowenoid papulosis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 1
- 125000004965 chloroalkyl group Chemical group 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 238000009904 heterogeneous catalytic hydrogenation reaction Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- NSHFLKZNBPJNPA-UHFFFAOYSA-N imidazo[4,5-c]quinolin-2-one Chemical class C1=CC=C2C3=NC(=O)N=C3C=NC2=C1 NSHFLKZNBPJNPA-UHFFFAOYSA-N 0.000 description 1
- AYMLKIRJIAFRKA-UHFFFAOYSA-N imidazo[4,5-c]quinoline-1-sulfonamide Chemical compound C1=CC=CC2=C3N(S(=O)(=O)N)C=NC3=CN=C21 AYMLKIRJIAFRKA-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- USJUUYYGHABIBU-UHFFFAOYSA-N methanesulfonamide;hydrochloride Chemical compound Cl.CS(N)(=O)=O USJUUYYGHABIBU-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- GVVGTUISEJMHQM-UHFFFAOYSA-N n-[3-(2-butyl-5-oxidoimidazo[4,5-c]quinolin-5-ium-1-yl)propyl]benzenesulfonamide Chemical compound CCCCC1=NC2=C[N+]([O-])=C3C=CC=CC3=C2N1CCCNS(=O)(=O)C1=CC=CC=C1 GVVGTUISEJMHQM-UHFFFAOYSA-N 0.000 description 1
- CNDBXITWFDAPKY-UHFFFAOYSA-N n-[3-(2-butyl-5-oxidoimidazo[4,5-c]quinolin-5-ium-1-yl)propyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCCNS(C)(=O)=O)C3=C[N+]([O-])=C21 CNDBXITWFDAPKY-UHFFFAOYSA-N 0.000 description 1
- YSRVRSNRDOIDKT-UHFFFAOYSA-N n-[3-(4-amino-2-methylimidazo[4,5-c]quinolin-1-yl)propyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(C)=N3)CCCNS(C)(=O)=O)C3=C(N)N=C21 YSRVRSNRDOIDKT-UHFFFAOYSA-N 0.000 description 1
- NPUKURXYLSVTBZ-UHFFFAOYSA-N n-[3-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydroimidazo[4,5-c]quinolin-1-yl]propyl]methanesulfonamide Chemical compound C1CCCC2=C(N(C(CCOC)=N3)CCCNS(C)(=O)=O)C3=C(N)N=C21 NPUKURXYLSVTBZ-UHFFFAOYSA-N 0.000 description 1
- RNOGFRHXFPQSIM-UHFFFAOYSA-N n-[3-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]propyl]-5-(dimethylamino)naphthalene-1-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)NCCCN3C4=C5C=CC=CC5=NC(N)=C4N=C3CCOC)=CC=CC2=C1N(C)C RNOGFRHXFPQSIM-UHFFFAOYSA-N 0.000 description 1
- GMDODJQAFXHURB-UHFFFAOYSA-N n-[4-(2-propylimidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide Chemical compound CCCC1=NC2=CN=C3C=CC=CC3=C2N1CCCCNS(=O)(=O)C1=CC=CC=C1 GMDODJQAFXHURB-UHFFFAOYSA-N 0.000 description 1
- LQDZOYWVFOTSOD-UHFFFAOYSA-N n-[4-(2-propylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CCC)=N3)CCCCNS(C)(=O)=O)C3=CN=C21 LQDZOYWVFOTSOD-UHFFFAOYSA-N 0.000 description 1
- RUKUTJCNUFLTPJ-UHFFFAOYSA-N n-[4-[4-amino-2-(cyclopropylmethyl)imidazo[4,5-c]quinolin-1-yl]butyl]methanesulfonamide Chemical compound N=1C2=C(N)N=C3C=CC=CC3=C2N(CCCCNS(=O)(=O)C)C=1CC1CC1 RUKUTJCNUFLTPJ-UHFFFAOYSA-N 0.000 description 1
- ZMSMSQMXTFIFJO-UHFFFAOYSA-N n-[8-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)octyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCCCCCCCNS(C)(=O)=O)C3=C(N)N=C21 ZMSMSQMXTFIFJO-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- VLCMRTMCMQJSKM-UHFFFAOYSA-N phenyl-[4-phenyl-8-(trifluoromethyl)quinolin-3-yl]methanone Chemical compound C=1C=CC=CC=1C(=O)C1=CN=C2C(C(F)(F)F)=CC=CC2=C1C1=CC=CC=C1 VLCMRTMCMQJSKM-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 102220013433 rs35141404 Human genes 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical group NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- PPHLYKFEQMEWND-UHFFFAOYSA-N tert-butyl n-[1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-yl]carbamate Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)NC(=O)OC(C)(C)C)C3=C(N)N=C21 PPHLYKFEQMEWND-UHFFFAOYSA-N 0.000 description 1
- ZYDRGNJWIFZPFN-UHFFFAOYSA-N tert-butyl n-[3-(2-butylimidazo[4,5-c]quinolin-1-yl)propyl]carbamate Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCCNC(=O)OC(C)(C)C)C3=CN=C21 ZYDRGNJWIFZPFN-UHFFFAOYSA-N 0.000 description 1
- ZXVBDXUTNLNKLL-UHFFFAOYSA-N tert-butyl n-[4-(2-ethylimidazo[4,5-c]quinolin-1-yl)butyl]carbamate Chemical compound C1=CC=CC2=C(N(C(CC)=N3)CCCCNC(=O)OC(C)(C)C)C3=CN=C21 ZXVBDXUTNLNKLL-UHFFFAOYSA-N 0.000 description 1
- HYECASNYJUMGQU-UHFFFAOYSA-N tert-butyl n-[4-(2-propylimidazo[4,5-c]quinolin-1-yl)butyl]carbamate Chemical compound C1=CC=CC2=C(N(C(CCC)=N3)CCCCNC(=O)OC(C)(C)C)C3=CN=C21 HYECASNYJUMGQU-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
WO 2005/003065 PCT/US2004/020607 Sulfonamide Substituted Imidazoquinolines Field of the Invention 5 This invention relates to imidazoquinoline compounds that have sulfonamide substitution at the 1-position and to pharmaceutical compositions containing the compounds. A further aspect of this invention relates to the use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases. 10 Background of the Invention The first reliable report on the 1H-imidazo[4,5-c]quinoline ring system, Backman et al., J. Org. Chem. 15, 1278-1284 (1950) describes the synthesis of 1-(6-methoxy-8 quinolinyl)-2-methyl-IH-imidazo[4,5-c]quinoline for possible use as an antimalarial 15 agent. Subsequently, syntheses of various substituted 1H-imidazo[4,5-c] quinolines were reported. For example, Jain et al., J. Med. Chem. 11, pp. 87-92 (1968), synthesized the compound 1-[2-(4-piperidyl)ethyl]-l1H-imidazo[4,5-c]quinoline as a possible anticonvulsant and cardiovascular agent. Also, Baranov et al., Chem. Abs. 85, 94362 (1976), have reported several 2-oxoimidazo[4,5-c]quinolines, and Berenyi et al., J. 20 Heterocyclic Chem. 18, 1537-1540 (1981), have reported certain 2-oxoimidazo[4,5 c]quinolines. Certain 1H-imidazo[4,5-c]quinolin-4-amines and 1- and 2-substituted derivatives thereof were later found to be useful as antiviral agents, bronchodilators and immunomodulators. These are described in, inter alia, U.S. Patent Nos. 4,689,338; 25 4,698,348; 4,929,624; 5,037,986; 5,268,376; 5,346,905; and 5,389,640, all of which are incorporated herein by reference. There continues to be interest in the imidazoquinoline ring system, as seen for example in WO 98/30562, EP 894 797 and WO 00/09506. EP 894 797 discloses amide substituted imidazoquinoline compounds that are disclosed to be useful as immune 30 response modifying compounds, while WO 00/09506 discloses imidazoquinoline compounds that contain a sulfonamide substituent wherein the sulfonamide nitrogen is part of a saturated heterocyclic ring. Despite these efforts, however, there is a continuing
I
WO 2005/003065 PCT/US2004/020607 need for compounds that have the ability to modulate the immune response, by induction of cytokine biosynthesis or other mechanisms. Summary of the Invention 5 We have found a new class of compounds that are useful in inducing cytokine biosynthesis in animals. Accordingly, this invention provides compounds of Formula I:
NH
2 N I R2 N R, (1) wherein R, R, and R 2 are as defined herein. 10 The compounds of Formula I are useful as immune response modifiers due to their ability to induce cytokine biosynthesis and otherwise modulate the immune reponse when administered to animals. This makes the compounds useful in the treatment of a variety of conditions such as viral diseases and tumors that are responsive to such changes in the immune response. 15 In one embodiment, compounds of the invention are selected from the group consisting of N-[4-(4-amino-2-ethyl- lH-imidazo[4,5-c]quinolin- 1 -yl)butyl]benzenesulfonamide; N-[4-(4-amino-2-propyl- 1H-imidazo[4,5-c]quinolin- 1 -yl)butyl]benzenesulfonamide; N-[4-(4-amino-2-hexyl- 1H-imidazo[4,5-c]quinolin- 1 -yl)butyl]benzenesulfonamide; 20 N-[4-(4-amino-2-propyl- 1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide; N-[4-(4-amino-2-ethyl- IH-imidazo[4,5-c]quinolin- 1 -yl)butyl]methanesulfonamide; N-[4-(4-amino-2-methyl- lH-imidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide; N-[4-(4-amino-2-methyl- lH-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide; N-[3-(4-amino-2-butyl- l H-imidazo[4,5-c]quinolin-1-yl)propyl]methanesulfonamide; 25 N-[3-(4-amino-2-butyl-IH-imidazo[4,5-c]quinolin-1-yl)propyl]benzenesulfonamide; N-[4-(4-amino-2-hexyl- 1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide; 2 WO 2005/003065 PCT/US2004/020607 N- { 8-[4-amino-2-(2-methoxyethyl)- 1H-imidazo[4,5-c]quinolin- 1 yl]octyl} benzenesulfonamide; N- { 8-[4-amino-2-(2-methoxyethyl)- 1H-imidazo[4,5-c]quinolin- 1 yl]octyl} methanesulfonamide; 5 N-[8-(4-amino-2-butyl-lH-imidazo[4,5-c]quinolin-1-yl)octyl]methanesulfonamide; N-[3 -(4-amino-2-butyl- I H-imidazo [4,5-c]quinolin- 1 -yl)propyl]-5 (dimethylamino)naphthalene- 1-sulfonamide; N-[3-(4-amino-2-butyl- I H-imidazo[4,5-c]quinolin- 1 -yl)propyl]-4 methylbenzenesulfonamide; 10 N- {3-[4-amino-2-(2-methoxyethyl)- 1H-imidazo[4,5-c]quinolin- 1 yl]propyl} methanesulfonamide; N-[8-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)octyl]benzenesulfonamide; N- {3-[4-amino-2-(2-methoxyethyl)- 1H-imidazo[4,5-c]quinolin- 1 yl]propyl} benzenesulfonamide; 15 N- [4-(4-amino-2-pentyl- 1H-imidazo[4,5-c]quinolin- 1 -yl)butyl]methanesulfonamide; N-[4-(4-amino-2-pentyl- 1H-imidazo[4,5-c]quinolin-1 -yl)butyl]benzenesulfonamide; N- [8-(4-amino- 1H-imidazo[4,5-c]quinolin- 1 -yl)octyl]methanesulfonamide; N- {3-[4-amino-2-(2-methoxyethyl)- 1H-imidazo[4,5-c]quinolin- I -yl]propyl}-4 methylbenzenesulfonamide; 20 N-[4-(4-amino-2-pentyl-6,7,8,9-tetrahydro-l IH-imidazo[4,5-c]quinolin-1 yl)butyl]methanesulfonamide; N- {3-[4-amino-2-(ethoxymethyl)- 1H-imidazo[4,5-c]quinolin-1 yl]propyl} methanesulfonamide; N- {3-[4-amino-2-(2-methoxyethyl)- 1H-imidazo[4,5-c]quinolin- 1 -yl]-2,2 25 dimethylpropyl} methanesulfonamide; N- {3-[4-amino-2-(2-methoxyethyl)-l1H-imidazo[4,5-c]quinolin-1-yl]propyl}-5 (dimethylamino)naphthalene- 1-sulfonamide; N-[3-(4-amino-2-methyl- 1H-imidazo[4,5-c]quinolin-1-yl)propyl]methanesulfonamide; N- { 3-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro- 1H-imidazo[4,5-c]quinolin- 1 30 yl]propyl}methanesulfonamide; N- {3-[4-amino-2-(ethoxymethyl)-6,7,8,9-tetrahydro- 1H-imidazo[4,5-c]quinolin- 1 yl]propyl} methanesulfonamide; 3 WO 2005/003065 PCT/US2004/020607 N- {3-[4-amino-2-(3-phenoxypropyl)- 1H-imidazo[4,5-c]quinolin- 1 yl]propyl} methanesulfonamide; N- {4-[4-amino-2-(3-phenoxypropyl)- 1H-imidazo[4,5-c]quinolin- 1 yl]butyl } methanesulfonamide; 5 N-[ 4 -(4-amino-2-methyl-6,7,8,9-tetrahydro- 1H-imidazo[4,5-c]quinolin- 1 yl)butyl]methanesulfonamide hydrochloride; N-[2-(4-amino-2-butyl- 1H-imidazo[4,5-c]quinolin- 1 -yl)ethyl]-4 methylbenzenesulfonamide; N-[2-(4-amino-2-butyl- 1H-imidazo[4,5-c]quinolin-1-yl)ethyl]methanesulfonamide; 10 1-[4-(1,1 -dioxidoisothiazolidin-2-yl)butyl]-2-(2-methoxyethyl)- IH-imidazo[4,5 c]quinolin-4-amine; 2-butyl-1 -[4-(1,1 -dioxidoisothiazolidin-2-yl)butyl]- 1H-imidazo[4,5-c]quinolin-4-amine; N- {2-[4-amino-2-(ethoxymethyl)- 1H-imidazo[4,5-c]quinolin-1-yl] -1,1 dimethylethyl} methanesulfonamide; 15 N-[4-(4-amino-2-methyl- 1 H-imidazo[4,5-c]quinolin- 1 -yl)butyl]ethanesulfonamide; 1-( 2 -amino-2-methylpropyl)-2-(ethoxymethyl)- 1H-imidazo[4,5-c]quinoline-4-amine; and N- { 4
-[
4 -amino-2-(cyclopropylmethyl)- 1H-imidazo[4,5-c]quinolin- 1 yl]butyl}methanesulfonamide; or a pharmaceutically acceptable salt thereof. 20 In a particularly prefered embodiment, a compound or salt of the invention is N- {2 [4-amino-2-(ethoxymethyl)- 1H-imidazo[4,5-c]quinolin- 1-yl]- 1, 1 dimethylethyl}methanesulfonamide or a pharmaceutically acceptable salt thereof. In addition to desirable formulation and toxicity properties, this compound has unexpectedly high IL-12 inducing activity relative to interferon (a) inducing activity. 25 The invention further provides pharmaceutial compositions containing a therapeutically effective amount of a compound or salt of Formula I or of the above embodiments and methods of inducing cytokine biosynthesis in an animal, treating a viral infection and/or treating a neoplastic disease in an animal by administering a effective amount of a compound or salt of Formula I or of the above embodiments to the animal. 30 In addition, methods of synthesizing compounds of Formula I and intermediates useful in the synthesis of these compounds are provided. 4 WO 2005/003065 PCT/US2004/020607 Detailed Description of the Invention As mentioned earlier, the invention provides compounds of Formula I:
NH
2 N N~ N R, RnR (I) 5 wherein
R
1 is -alkyl-NR 3 -SO2-X-R 4 , -alkenyl-NR 3
-SO
2
-X-R
4 , or alkyl-NR 6 -S0 2
-R
7 ; X is a bond or -NRs-;
R
4 is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be 10 unsubstituted or substituted by one or more substituents selected from the group consisting of: -alkyl; -alkenyl; -aryl; 15 -heteroaryl; -heterocyclyl; -substituted aryl; -substituted heteroaryl; -substituted heterocyclyl; 20 -O-alkyl; -O-(alkyl) 0
.
1 -aryl; -O-(alkyl) 0 o- -substituted aryl; -O-(alkyl)o 1 .- heteroaryl; -O-(alkyl)o- 0 1 l-substituted heteroaryl; 25 -O-(alkyl)o- 1 -heterocyclyl; -O-(alkyl)o-l-substituted heterocyclyl; 5 WO 2005/003065 PCT/US2004/020607 -COOH; -CO-O-alkyl; -CO-alkyl;
-S(O)
0
-
2 -alkyl; 5 -S(O) 0
-
2 -(alkyl)o 1 -aryl;
-S(O)
0
-
2 -(alkyl)o -substituted aryl;
-S(O)
0
-
2 -(alkyl)o.
1 -heteroaryl;
-S(O)
0 -2-(alkyl)o_ -substituted heteroaryl;
-S(O)
0 -2 -(alkyl)o- -heterocyclyl; 10 -S(O)o.0- 2 -(alkyl)o.-substituted heterocyclyl; -(alkyl)o- 1
-NR
3
R
3 ; -(alkyl)o 1
-NR
3 -CO-O-alkyl; -(alkyl)o.-NR 3 -CO-alkyl; -(alkyl)o_1 -NR 3 -CO-aryl; 15 -(alkyl)o1-NR 3 -CO-substituted aryl; -(alkyl) 01
-NR
3 -CO-heteroaryl; -(alkyl) 0 o_-NR 3 -CO-substituted heteroaryl;
-N
3 ; -halogen; 20 -haloalkyl; -haloalkoxy; -CO-haloalkoxy;
-NO
2 ; -CN; 25 -OH; -SH; and in the case of alkyl, alkenyl, or heterocyclyl, oxo;
R
2 is selected from the group consisting of: -hydrogen; 30 -alkyl; -alkenyl; -aryl; 6 WO 2005/003065 PCT/US2004/020607 -substituted aryl; -heteroaryl; -substituted heteroaryl; -alkyl-O-alkyl; 5 - alkyl-O- alkenyl; and -alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH; -halogen; 10 -N(R3)2; -CO-N(R3)2; -CO-C-o 10 alkyl; -CO-O-C-o 0 alkyl; -N 3 ; 15 -aryl; -substituted aryl; -heteroaryl; -substituted heteroaryl; -heterocyclyl; 20 -substituted heterocyclyl; -CO-aryl; -CO-(substituted aryl); -CO-heteroaryl; and -CO-(substituted heteroaryl); 25 each R 3 is independently selected from the group consisting of hydrogen and Cllo 10 alkyl; Rs is selected from the group consisting of hydrogen and C-o 0 alkyl, or R 4 and Rs can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring;
R
6 is selected from the group consisting of hydrogen and C- 0 o alkyl; 30 R 7 is selected from the group consisting of hydrogen and C- 1 o alkyl, wherein R 6 and R 7 combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring; 7 WO 2005/003065 PCT/US2004/020607 n is 0 to 4 and each R present is independently selected from the group consisting of Ci- 1 0 alkyl, C 1
-
1 0 alkoxy, halogen and trifluoromethyl, or a pharmaceutically acceptable salt thereof. 5 Preparation of the Compounds Imidazoquinolines of the invention can be prepared according to Reaction Scheme I where R, RI, R 2 and n are as defined above. In step (1) of Reaction Scheme I a 4-chloro-3-nitroquinoline of Formula II is reacted with an amine of Formula RINH11 2 where Rl is as defined above to provide a 3 10 nitroquinolin-4-amine of Formula III. The reaction can be carried out by adding amine to a solution of a compound of Formula II in a suitable solvent such as chloroform or dichloromethane and optionally heating. Many quinolines of Formula II are known compounds (see for example, U.S. Patent 4,689,338 and references cited therein). In step (2) of Reaction Scheme I a 3-nitroquinolin-4-amine of Formula III is 15 reduced to provide a quinoline-3,4-diamine of Formula IV. Preferably, the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon or palladium on carbon. The reaction can conveniently be carried out on a Parr apparatus in a suitable solvent such as isopropyl alcohol or toluene. In step (3) of Reaction Scheme I a quinoline-3,4-diamine of Formula IV is reacted 20 with a carboxylic acid or an equivalent thereof to provide a 1H-imidazo[4,5-c]quinoline of Formula V. Suitable equivalents to carboxylic acid include acid halides, orthoesters, and 1,1-dialkoxyalkyl alkanoates. The carboxylic acid or equivalent is selected such that it will provide the desired R 2 substituent in a compound of Formula V. For example, triethyl orthoformate will provide a compound where R 2 is hydrogen and triethyl orthoacetate will 25 provide a compound where R 2 is methyl. The reaction can be run in the absence of solvent or in an inert solvent such as toluene. The reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction. In step (4) of Reaction Scheme I a 1H-imidazo[4,5-c]quinoline of Formula V is oxidized to provide a 1H-imidazo[4,5-c]quinoline-5N-oxide of Formula VI using a 30 conventional oxidizing agent that is capable of forming N-oxides. Preferred reaction conditions involve reacting a solution of a compound of Formula V in chloroform with 3 chloroperoxybenzoic acid at ambient conditions. 8 WO 2005/003065 PCT/US2004/020607 In step (5) of Reaction Scheme I a 1H-imidazo[4,5-c]quinoline-5N-oxide of Formula VI is aminated to provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula VII which is a subgenus of Formula I. Step (5) involves (i) reacting a compound of Formula VI with an acylating agent and then (ii) reacting the product with an aminating agent. Part 5 (i) of step (5) involves reacting an N-oxide of Formula VI with an acylating agent. Suitable acylating agents include alkyl- or arylsulfonyl chlorides (e.g., benezenesulfonyl chloride, methanesulfonyl chloride, p-toluenesulfonyl chloride). Arylsulfonyl chlorides are preferred. Para-toluenesulfonyl chloride is most preferred. Part (ii) of step (5) involves reacting the product of part (i) with an excess of an aminating agent. Suitable 10 aminating agents include ammonia (e.g., in the form of ammonium hydroxide) and ammonium salts (e.g., ammonium carbonate, ammonium bicarbonate, ammonium phosphate). Ammonium hydroxide is preferred. The reaction is preferably carried out by dissolving the N-oxide of Formula VI in an inert solvent such as dichloromethane, adding the aminating agent to the solution, and then slowly adding the acylating agent. The 15 product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. Alternatively, step (5) may be carried out by (i) reacting an N-oxide of Formula VI with an isocyanate and then (ii) hydrolyzing the resulting product. Part (i) involves reacting the N-oxide with an isocyanate wherein the isocyanato group is bonded to a 20 carbonyl group. Preferred isocyanates include trichloroacetyl isocyanate and aroyl isocyanates such as benzoyl isocyanate. The reaction of the isocyanate with the N-oxide is carried out under substantially anhydrous conditions by adding the isocyanate to a solution of the N-oxide in an inert solvent such as chloroform or dichloromethane. Part (ii) involves hydrolysis of the product from part (i). The hydrolysis can be carried out by 25 conventional methods such as heating in the presence of water or a lower alkanol optionally in the presence of a catalyst such as an alkali metal hydroxide or lower alkoxide. 30 9 WO 2005/003065 PCT/US2004/020607 Reaction Scheme I N NO 2
NO
2 N \ NH 2 I II CI (1) NH (2) NH Rn R IR I II III IV S(3)
NH
2 N N 0 'N+ N N N I \> I R2 R2 R2 N (5) - N (4) N Rn/ Rn/ R R n R n in niK VII VI V Compounds of the invention where the R, substituent contains a sulfonamide can 5 also be prepared according to Reaction Scheme II where R, R 2 , R 4 and n are as defined above and m is 1-20. In Reaction Scheme II an aminoalkyl substituted 1H-imidazo[4,5-c]quinolin-4 amine of Formula VIII is reacted with a sulfonyl chloride of Formula IX to provide a compound of Formula X which is a subgenus of Formula I. The reaction can be run at 10 ambient temperature in an inert solvent such as dichloromethane in the presence of a base such as pyridine or N,N-diisopropylethylamine. Many 1H-imidazo[4,5-c]quinolin-4 amines of Formula VIII are known compounds, see for example US Patent 6,069,149 (Namba); others can be readily prepared using known synthetic methods. Many sulfonyl chlorides of Formula IX are commercially available; others can be readily prepared using 15 known synthetic methods. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. 10 WO 2005/003065 PCT/US2004/020607 Reaction Scheme II
NH
2 NH 2 N N 0N N I + R-S-CI R R (CH2 ) I(H~ I
NH
2 NH VIII IX X O=S=O I R4 Compounds of the invention where the R 1 substituent contains a sulfonamide can also be prepared according to Reaction Scheme III where R, R 2 , R 4 and n are as defined 5 above and m is 1-20. In Reaction Scheme III an aminoalkyl substituted 1H-imidazo[4,5-c]quinolin-4 amine of Formula VIII is reacted with a sulfonic anhydride of Formula XI to provide a compound of Formula X which is a subgenus of Formula I. The reaction can be run at ambient temperature in an inert solvent such as dichloromethane in the presence of a base 10 such as pyridine or N,N-diisopropylethylamine. Alternatively, the reaction can be run at ambient temperature in acetonitrile. Many sulfonic anhydrides of Formula XI are commercially available; others can be readily prepared using known synthetic methods. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. 15 Reaction Scheme III
NH
2 NH 2 N N 0 0 N N O- O1 1 N N I + R-S-O-S- R N R "N " 1 4 R I o o "N 1 0 0N R (CH 2 ) m R S (CH 2 ) M
NH
2 NH VIII XI X O=S=0 I R4 Tertiary sulfonamides of the invention can be prepared according to Reaction Scheme IV where R, R 2 , R 3 , R4 and n are as defined above and m is 1-20. 20 In Reaction Scheme IV a 1H-imidazo[4,5-c]quinolinyl sulfonamide of Formula X is reacted with a halide of Formula XII to provide a compound of Formula XIII which is a 11 WO 2005/003065 PCT/US2004/020607 subgenus of Formula I. The reaction can be carried out at ambient temperature by adding sodium hydride to a solution of a compound of Formula X in N,N-dimethylformamide and then adding the halide. Many halides of Formula XII are commercially available; others can be readily prepared using known synthetic methods. The product or a 5 pharmaceutically acceptable salt thereof can be isolated using conventional methods. Reaction Scheme IV
NH
2 NH 2 N N N N I R2 + R 3 Hal I R2 N rN n / (CH2)m Rn (CH2)m I I NH N X O=S=O XII XIII R30=SO
R
4 R 4 10 Compounds of the invention where R, contains a sulfamide group can be prepared according to Reaction Scheme V wherein R, R 2 , R 4 , R 5 and n are as defined above and m is 1-20. In step (1) of Reaction Scheme V an aminoalkyl substituted 1H-imidazo[4,5 c]quinolin-4-amine of Formula VIII is reacted with sulfuryl chloride to generate in situ a 15 sulfamoyl chloride of Formula XIV. The reaction can be carried out by adding a solution of sulfuryl chloride in dichloromethane to a solution of a compound of Formula VIII in dichloromethane in the presence of one equivalent of 4-(dimethylamino)pyridine. The reaction is preferably carried out at a reduced temperature (-78 0 C). Optionally, after the addition is complete the reaction mixture can be allowed to warm to ambient temperature. 20 In step (2) of Reaction Scheme V an amine of Formula RsR4NH is reacted with the sulfamoyl chloride of Formula XIV to provide a 1H-imidazo[4,5-c]quinolinyl sulfamide of Formula XV which is a subgenus of Formula I. The reaction can be carried out by adding a solution containing 2 equivalents of the amine and 2 equivalents of triethylamine in dichloromethane to the reaction mixture from step (1). The addition is preferably carried 25 out at a reduced temperature (-78 0 C). After the addition is complete the reaction mixture can be allowed to warm to ambient temperature. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. 12 WO 2005/003065 PCT/US2004/020607 Reaction Scheme V
NH
2
NH
2
NH
2 N N S0 2 C1 2 N N RR 4 NH N N I- R 2 | -0-R 2 \>| R, /-N (1) N (2) / N I I I A rC2) N 2) M (
NH
2 HN HN OoS=O -A=O VIII XIV Cl XV N R/
R
4 Tetrahydroimidazoquinolines of the invention can be prepared according to 5 Reaction Scheme VI where R 2 , R 3 , R 4 , and R 5 are as defined above and m is 1-20. In step (1) of Reaction Scheme VI an aminoalkyl substituted 1H-imidazo[4,5 c]quinolin-4-amine of Formula XVI is reduced to provide an aminoalkyl substituted 6,7,8,9-tetrahydro-IH-imidazo[4,5-c]quinolin-4-amine of Formula XVII. Preferably the reduction is carried out by suspending or dissolving the compound of Formula XVI in 10 trifluoroacetic acid, adding a catalytic amount of platinum (IV) oxide, and then subjecting the mixture to hydrogen pressure. The reaction can conveniently be carried out on a Parr apparatus. The product or a salt thereof can be isolated using conventional methods. In step (2a) of Reaction Scheme VI an aminoalkyl substituted 6,7,8,9-tetrahydro 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVII is reacted to provide a compound of 15 Formula XVIII which is a subgenus of Formula I. When R 3 is hydrogen, the reaction can be carried out in one step according to the methods described in Reaction Schemes II and III above using a tetrahydroimidazoquinoline of Formula XVII in place of the imidazoquinoline of Formula VIII. When R 3 is other than hydrogen, the reaction can be carried out in two steps with step one being carried out according to the methods of 20 Reaction Schemes II and III and step two being carried out according to the method of Reaction IV using the tetrahydroimidazoquinoline analog of the imidazoquinoline. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. In step (2b) of Reaction Scheme VI an aminoalkyl substituted 6,7,8,9-tetrahydro 25 1H-imidazo[4,5-c]quinolin-4-amine of Formula XVII is reacted to provide a compound of Formula XIX which is a subgenus of Formula I. The reaction can be carried out according 13 WO 2005/003065 PCT/US2004/020607 to the method described in Reaction Scheme V using a tetrahydroimidazoquinoline of Formula XVII in place of the imidazoquinoline of Fornmula VIII. The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. 5 Reaction Scheme VI
NH
2 N N I -R 2
NH
2 NH2 N 2 N N ,~ NI NI IR NI R (2a) (CH 2 ) N (1) N SR3XVIII R N'S O N (CH 2 m
(CH
2 ) m R4 NH, NH 2 XVI XVII (2b) NH 2 |\> R2 N
(CH
2 ) HN , O XIX ,/H OR/ N'R4 5 Tetrahydroimidazoquinolines of the invention can also be prepared according to Reaction Scheme VII where R, R 2 , R 3 , R 4 , R 5 and n are as defined above and m is 1-20. 10 In step (1) of Reaction Scheme VII a 6,7,8,9-tetrahydro-lH-imidazo[4,5 c]quinolinyl tert-butylcarbamate of Formula XX is hydrolyzed to provide an aminoalkyl substituted 6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine of Formula XXI. The reaction can be carried out dissolving the compound of Formula XX in a mixture of trifluoroacetic acid and acetonitrile and stirring at ambient temperature. Alternatively, the 15 compound of Formula XX can be combined with dilute hydrochloric acid and heated on a steam bath. Tetrahydro-1H-imidazo[4,5-c]quinolinyl tert-butylcarbamates of Formula XX can be prepared using the synthetic route disclosed in U.S. Patent 5,352,784 (Nikolaides). The product or a salt thereof can be isolated using conventional methods. Steps (2a) and (2b) can be carried out in the same manner as in Reaction Scheme 20 VI. 14 WO 2005/003065 PCT/US2004/020607 Reaction Scheme VII
NH
2 N N
NH
2 NH (2a) N 2 N R2R2 R I N (nH 2 ) S N (1) N O XXII R NS'
(CH
2 ) Rn (CH 2 )m 0o' R 4 HN NH 2 XX >O0 XXI (2b) NH 0 2 N N I Rn (CH 2 ) HN, O XXIII O \H 0 NFR4 R4 Some compounds of Formula I can be readily prepared from other compounds of Formula I. For example, compounds wherein the R4 substituent contains a chloroalkyl 5 group can be reacted with an amine to provide an R 4 substituent substituted by a secondary or teriary amino group; compounds wherein the R 4 substituent contains a nitro group can be reduced to provide a compound wherein the R4 substituent contains a primary amine. As used herein, the terms "alkyl", "alkenyl", "alkynyl" and the prefix "-alk" are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e. 10 cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to 20 carbon atoms, with alkenyl and alkynyl groups containing from 2 to 20 carbon atoms. Preferred groups have a total of up to 10 carbon atoms. Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopentyl, cyclohexyl and adamantyl. 15 The term "haloalkyl" is inclusive of groups that are substituted by one or more halogen atoms, including groups wherein all of the available hydrogen atoms are replaced by halogen atoms. This is also true of groups that include the prefix "haloalk-". Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like. The term "aryl" as used herein includes carbocyclic aromatic rings or ring systems. 20 Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl. The 15 WO 2005/003065 PCT/US2004/020607 term "heteroaryl" includes aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N). Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, tetrazolyl, imidazo, pyrazolo, thiazolo, oxazolo, and the like. "Heterocyclyl" includes non-aromatic rings or ring systems that contain at least 5 one ring hetero atom (e.g., O, S, N). Exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, and the like. Unless otherwise specified, the terms "substituted cycloalkyl", "substituted aryl", "substituted heteroaryl" and "substituted heterocyclyl" indicate that the rings or ring 10 systems in question are further substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, alkylthio, hydroxy, halogen, haloalkyl, haloalkylcarbonyl, haloalkoxy (e.g., trifluoromethoxy), nitro, alkylcarbonyl, alkenylcarbonyl, arylcarbonyl, heteroarylcarbonyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocycloalkyl, nitrile, alkoxycarbonyl, 15 alkanoyloxy, alkanoylthio, and in the case of cycloalkyl and heterocyclyl, oxo. In structural formulas representing compounds of the invention certain bonds are represented by dashed lines. These lines mean that the bonds represented by the dashed line can be present or absent. Accordingly, compounds of Formula I can be either imidazoquinoline compounds or tetrahydroimidazoquinoline compounds. 20 The invention is inclusive of the compounds described herein in any of their pharmaceutically acceptable forms, including isomers such as diastereomers and enantiomers, salts, solvates, polymorphs, and the like. Pharmaceutical Compositions and Biological Activity 25 Pharmaceutical compositions of the invention contain a therapeutically effective amount of a compound of Formula I in combination with a pharmaceutically acceptable carrier. As used herein, the term "a therapeutically effective amount" means an amount of the compound sufficient to induce a therapeutic effect, such as cytokine induction, 30 antitumor activity and/or antiviral activity. Although the exact amount of active compound used in a pharmaceutical composition of the invention will vary according to factors known to those of skill in the art, such as the physical and chemical nature of the 16 WO 2005/003065 PCT/US2004/020607 compound as well as the nature of the carrier and the intended dosing regimen, it is anticipated that the compositions of the invention will contain sufficient active ingredient to provide a dose of about 100Ong/kg to about 50mg/kg, preferably about 10g/kg to about 5mg/kg of the compound to the subject. Any of the conventional dosage forms may be 5 used, such as tablets, lozenges, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmucosal patches and the like. The compounds of the invention have been shown to induce the production of certain cytokines in experiments performed according to the tests set forth below. These results indicate that the compounds are useful as immune response modifiers that can 10 modulate the immune response in a number of different ways, rendering them useful in the treatment of a variety of disorders. Cytokines that may be induced by the administration of compounds according to the invention generally include interferon-a (IFN-a) and tumor necrosis factor-a (TNF-a) as well as certain interleukins (IL). Cytokines whose biosynthesis may be induced by 15 compounds of the invention include IFN-a, TNF-a, IL-1, 6, 10 and 12, and a variety of other cytokines. Among other effects, cytokines inhibit virus production and tumor cell growth, making the compounds useful in the treatment of viral diseases and tumors. In addition to the ability to induce the production of cytokines, the compounds of the invention affect other aspects of the innate immune response. For example, natural 20 killer cell activity may be stimulated, an effect that may be due to cytokine induction. The compounds may also activate macrophages, which in turn stimulates secretion of nitric oxide and the production of additional cytokines. Further, the compounds may cause proliferation and differentiation of B-lymphocytes. Compounds of the invention also have an effect on the acquired immune response. 25 For example, although there is not believed to be any direct effect on T cells or direct induction of T cell cytokines, the production of the T helper type 1 (Thl) cytokine IFN-y is induced indirectly and the production of the T helper type 2 (Th2) cytokines IL-4, IL-5 and IL-13 are inhibited upon administration of the compounds. This activity means that the compounds are useful in the treatment of diseases where upregulation of the Thl 30 response and/or downregulation of the Th2 response is desired. In view of the ability of compounds of Formula Ia to inhibit the Th2 immune response, the compounds are expected to be useful in the treatment of atopic diseases, e.g., atopic dermatitis, asthma, 17 WO 2005/003065 PCT/US2004/020607 allergy, and allergic rhinitis; and systemic lupus erythematosis; as a vaccine adjuvant for cell mediated immunity; and possibly as a treatment for recurrent fungal diseases and chlamydia. The immune response modifying effects of the compounds make them useful in 5 the treatment of a wide variety of conditions. Because of their ability to induce the production of cytokines such as IFN-a and/or TNF-a, the compounds are particularly useful in the treatment of viral diseases and tumors. This immunomodulating activity suggests that compounds of the invention are useful in treating diseases such as, but not limited to, viral diseases including genital warts; common warts; plantar warts; Hepatitis 10 B; Hepatitis C; Herpes Simplex Virus Type I and Type II; molluscum contagiosum; HIV; CMV; VZV; intraepithelial neoplasias such as cervical intraepithelial neoplasia; human papillomavirus (HPV) and associated neoplasias; fungal diseases, e.g. candida, aspergillus, and cryptococcal meningitis; neoplastic diseases, e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous 15 leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers; parasitic diseases, e.g. pneumocystis carnii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection, leishmaniasis; and bacterial infections, e.g., tuberculosis, mycobacterium avium. Additional diseases or conditions that can be treated using the compounds of the invention include eczema; 20 eosinophilia; essential thrombocythaemia; leprosy; multiple sclerosis; Ommen's syndrome; discoid lupus; Bowen's disease; Bowenoid papulosis; and to enhance or stimulate the healing of wounds, including chronic wounds. Accordingly, the invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound of Formula I to 25 the animal. An amount of a compound effective to induce cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, IFN-o, TNF-a, IL-1, 6, 10 and 12 that is increased over the background level of such cytokines. The precise amount will vary according to factors known in the art but is 30 expected to be a dose of about 100 ng/kg to about 50mg/kg, preferably about 10 g/kg to about 5mg/kg. The invention also provides a method of treating a viral infection in an animal, and a method of treating a neoplastic disease in an animal, comprising 18 WO 2005/003065 PCT/US2004/020607 administering an effective amount of a compound of Formula I to the animal. An amount effective to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals. The precise 5 amount will vary according to factors known in the art but is expected to be a dose of 100Ong/kg to about 50mg/kg, preferably about 10pg/kg to about 5mg/kg. An amount of a compound effective to treat a neoplastic condition is an amount that will cause a reduction in tumor size or in the number of tumor foci. Again, the precise amount will vary according to factors known in the art but is expected to be a dose of about 100 Ong/kg to 10 about 50mg/kg, preferably about 10tg/kg to about 5mg/kg. The invention is further described by the following examples, which are provided for illustration only and are not intended to be limiting in any way. 15 Example 1 N-[4-(4-amrnino-2-ethyl- 1H-imidazo[4,5-c]quinolin- 1 -yl)butyl]benzenesulfonamide
NH
2 NN N 0 HN,.. Triethylamine (1.18 mL, 8.5 mmol) was added to a mixture of 1-(4-aminobutyl)-2 ethyl-1H-imidazo[4,5-c]quinolin-4-amine (2.00 g, 7.1 mmol) and chloroform (200 mL). 20 The resulting solution was chilled in an acetone/ice bath for 10 minutes. Benzenesulfonyl chloride (0.90 mL, 8.5 mmol) was slowly added over a period of 5 minutes. After 45 minutes 0.2 equivalents oftriethylamine was added. After 6 hours the reaction mixture was washed with brine (2 x 250 mL) and with water (1 x 100 mL), dried over magnesium sulfate and then concentrated under reduced pressure. The residue was recrystallized from 25 N,N-dimethylformamide. The recrystallized material and the filtrate were both slurried with methanol. The resulting solids were isolated by filtration, combined, and then dried 19 WO 2005/003065 PCT/US2004/020607 in an Abderhalden drying apparatus overnight to provide 0.80 g of N-[4-(4-amino-2-ethyl 1H-imidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide as a white solid, m.p. 180.6 182.0 0 C. Analysis: Calculated for C 22
H
25
N
5 0 2 S -0.25 H 2 0: %C, 61.73; %H, 6.00; %N, 16.36; Found: %C, 61.79; %H, 6.04; %N, 16.43. 5 Example 2 N-[4-(4-amino-2-propyl 1H-imidazo[4,5-c]quinolin-1 -yl)butyl]benzenesulfonamide
NH
2 N 0 HN, , 10 Part A Tert-butyl 4-(2-propyl-lH-imidazo[4,5-c]quinolin-1-yl)butylcarbamate (5.00 g, 13.1 mmol) was combined with hydrochloric acid (50 mL of 4.0 M in dioxane) and stirred for 1.5 hours. The reaction mixture was diluted with dichloromethane (-200 mL). Saturated sodium bicarbonate solution was added until a pH of 8 was obtained. A 15 precipitate formed in the aqueous phase. The layers were separated. The precipitate in the aqueous layer was isolated by filtration, slurried with water and then isolated by filtration to provide 3.6 g of 4-(2-propyl- lH-imidazo[4,5-c]quinolin- 1 -yl)butan- 1-amine. Part B The material from Part A was combined with chloroform (600 mL) and warmed to 20 40'C. Triethylamine (3.48 mL, 25 mmol) was added and a solution was obtained. Benzenesulfonyl chloride (1.60 mL, 12.5 mmol) was added. The reaction mixture was stirred at 40oC overnight. The reaction mixture was cooled to ambient temperature and then concentrated under reduced pressure. The residue was taken up in dichloromethane (-100 mL), washed with water (3 x 125 mL), dried over magnesium sulfate and then 25 concentrated under reduced pressure to provide 3.96 g of N-[4-(2-propyl-1H-imidazo[4,5 20 WO 2005/003065 PCT/US2004/020607 c]quinolin-1-yl)butyl]benzenesulfonamide as a yellow crystalline solid, m.p. 155.9 157.1 0 C. Part C 3-Chloroperoxybenzoic acid (896 mg of 77%) was added over a period of 5 5 minutes to a solution of N-[4-(2-propyl- IH-imidazo[4,5-c]quinolin-1 yl)butyl]benzenesulfonamide (1.0 g, 2.4 mmol) in chloroform (100 mL). After 2.5 hours an additional 0.1 equivalent of 3-chloroperoxybenzoic acid was added. After 3 hours the reaction was stored at a reduced temperature overnight. The reaction mixture was washed with saturated sodium bicarbonate solution (3 x 150 mL) and then concentrated under 10 reduced pressure to provide 1.44 g of crude product. This material was recrystallized from methyl acetate to provide 0.67 g of 1-{4-[(phenylsulfonyl)amino]butyl}-2-propyl-1H imidazo[4,5-c]quinolin-5N-oxide as a brown solid, m.p. 203.8-205.2oC. Part D Ammonium hydroxide (3.5 mL of 27%) was added to a mixture of the material 15 from Part C and dichloromethane (15 mL). After 10 minutes tosyl chloride (0.35 g) was slowly added over a period of 5 minutes. After 45 minutes the reaction mixture was stored at a reduced temperature over the weekend. An additional 35 mg of tosyl chloride was added and the reaction mixture was stirred for 1 hour. The organic phase was separated and then washed with saturated sodium bicarbonate solution (3 x 80 mL). A precipitate 20 formed in the aqueous phase. This material was isolated by filtration and then recrystallized from methyl acetate. The resulting solid and the filtrate were combined, dissolved in dichloromethane containing a small amount of methanol, and then purified by column chromatography (silica gel eluting with 10% methanol in dichloromethane). The resulting material was purified by column chromatography (silica gel eluting with 0-7.5% 25 methanol in dichloromethane). This material was recrystallized 3 times from methyl acetate to provide 42 mg of N-[4-(4-amino-2-propyl-IH-imidazo[4,5-c]quinolin-1 yl)butyl]benzenesulfonamide as a white solid, m.p. 158.8-160.8 0 C. Analysis: Calculated for C 2 3
H
2 7
N
5 0sO 2 S -0.25 C 3
H
6 0 2 : %C, 62.15; %H, 6.22; %N, 15.59; Found: %C, 62.41; %H, 5.91; %N, 15.41. 30 21 WO 2005/003065 PCT/US2004/020607 Example 3 N-[4-(4-amino-2-hexyl- 1 H-imidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide
NH
2 N 0I Part A 5 Using the general method of Example 2 Part A, tert-butyl 4-(2-hexyl-IH imidazo[4,5-c]quinolin-1-yl)butylcarbamate (33.85 g) was hydrolyzed to provide 3.43 g of 4-(2-hexyl-l1H-imidazo[4,5-c]quinolin-1-yl)butan-l1-amine as an off white solid, m.p. 172.2-174.2 0 C. Part B 10 Using the general method of Example 2 Part B except that the reaction was run at ambient temperature, 4-(2-hexyl-1H-imidazo[4,5-c]quinolin-1-yl)butan-1-amine (1.20 g, 3.7 mmol) was reacted with benzenesulfonyl chloride (429 tL, 3.7 mmol) to provide 0.75 g of N-[4-(2-hexyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide as a light yellow solid, m.p. 137.0-138.1oC. 15 Part C Using the general method of Example 2 Part C, N-[4-(2-hexyl-1H-imidazo[4,5 c]quinolin-1-yl)butyl]benzenesulfonamide (0.95 g, 2.0 mmol) was oxidized to provide 1.21 g of crude 1-{4-[(phenylsulfonyl)amino]butyl}-2-hexyl-lH-imidazo[4,5-c]quinolin 5N-oxide. 20 Part D Using the general method of Example 2 Part D, the material from Part C was aminated to provide 118 mg of N-[4-(4-amino-2-hexyl-1H-imidazo[4,5-c]quinolin-1 yl)butyl]benzenesulfonamide as an off white crystalline solid, m.p. 84.8-85.4oC. Analysis: Calculated for C 2 6
H
3 3
N
5 0 2 S • 0.5 H 2 0: %C, 63.91; %H, 7.01; %N, 14.33; Found: %C, 25 63.63; %H, 6.93; %N, 14.80. 22 WO 2005/003065 PCT/US2004/020607 Example 4 N-[4-(4-amino-2-propyl 1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide
NH
2 N
HS-
0 0 5 Part A Using the general method of Example 2 Part B except that the reaction was run at ambient temperature, 4-(2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butan-l1-amine (2.00 g, 7.1 mmol) was reacted with methanesulfonyl chloride (1.65 mL, 21.3 mmol) to provide 1.23 g of N-[4-(2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide as a 10 light yellow solid, m.p. 133.2-134.6 0 C. Part B Using the general method of Example 2 Part C, N-[4-(2-propyl-lH-imidazo[4,5 c]quinolin-1-yl)butyl]methanesulfonamide was oxidized to provide 1.44 g of crude 1-{4 [(methylsulfonyl)amino]butyl} -2-propyl-1H-imidazo[4,5-c]quinolin-5N-oxide asa light 15 yellow solid. Part C Using the general method of Example 2 Part D, the material from Part B was aminated to provide 0.21 g of N-[4-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1 yl)butyl]methanesulfonamide as an off white crystalline solid, m.p. 186.5-187.9oC. 20 Analysis: Calculated for C 18
H
2 5
N
5 0 2 S -0.25 H 2 0: %C, 56.89; %H, 6.76; %N, 18.43; Found: %C, 56.95; %H, 6.89; %N, 18.13. 23 WO 2005/003065 PCT/US2004/020607 Example 5 N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide
NH
2 N O H 11 0 Part A 5 Using the general method of Example 2 Part A, tert-butyl 4-(2-ethyl-1H imidazo[4,5-c]quinolin-1-yl)butylcarbamate (20.69 g) was hydrolyzed to provide 14.94 g of 4-(2-ethyl- 1H-imidazo[4,5-c]quinolin- 1-yl)butan- 1-amine as an off white solid, m.p. 84.8-88.7 0 C. Part B 10 Using the general method of Example 2 Part B, 4-(2-ethyl-1H-imidazo[4,5 c]quinolin-1-yl)butan-1-amine (4.00 g, 14. 9 mmol) was reacted with methanesulfonyl chloride to provide 1.78 g of N-[4-(2-ethyl-l1H-imidazo[4,5-c]quinolin-1 yl)butyl]methanesulfonamide as a light yellow solid. Part C 15 Using the general method of Example 2 Part C, the material from Part B was oxidized to provide -2.00 g of crude 1-{4-[(methylsulfonyl)amino]butyl}-2-ethyl-1H imidazo[4,5-c]quinolin-5N-oxide. Part D Using the general method of Example 2 Part D, the material from Part C was 20 aminated to provide 0.42 g of N-[4-(4-amino-2-ethyl-IH-imidazo[4,5-c]quinolin-1 yl)butyl]methanesulfonamide as a white solid, m.p. 203.3-204.4 0 C. Analysis: Calculated for C 17
H
23
N
5 0 2 S: %C, 56.49; %H, 6.41; %N, 19.37; Found: %C, 56.21; %H. 6.36; %N, 19.09. 24 WO 2005/003065 PCT/US2004/020607 Example 6 N-[4-(4-amino-2-methyl 1H-imidazo[4,5-c]quinolin-1 -yl)butyl]benzenesulfonamide
NH
2 N N /N O 0 HN, 5 Using the general method of Example 1, 1-(4-aminobutyl)-2-methyl-1H imidazo[4,5-c]quinolin-4-amine (0.50 g, 1.9 mmol) was reacted with benzenesulfonyl chloride (0.24 mL, 1.9 mmol) to provide 0.38 g of N-[4-(4-amino-2-methyl-lH imidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide as brown granules, m.p. 215.4 216.0oC. Analysis: Calculated for C 2 1
H
2 3
N
5 0 2 S: %C, 61.59; %H, 5.66; %/oN, 17.10; Found: 10 %C, 61.24; %H, 5.65; %N, 16.95. Example 7 N-[4-(4-amino-2-methyl 1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide
NH
2 N 0
HN
S 15 O Using the general method of Example 1, 1-(4-aminobutyl)-2-methyl-1H imidazo[4,5-c]quinolin-4-amine (1.00 g, 3.7 mmol) was reacted with methanesulfonyl chloride (0.46 mL, 5.9 mmol) to provide 0.16 g of N-[4-(4-amino-2-methyl-1H imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide as an off white solid, m.p. 229.4 20 230.5oC. Analysis: Calculated for C, 6
H
21
N
5 0 2 S -0.25 H 2 0: %C, 54.60; %H, 6.16; %N, 19.90; Found: %C, 54.80; %H, 6.24; %N, 19.58. 25 WO 2005/003065 PCT/US2004/020607 Example 8 N-[3-(4-amino-2-butyl 1H-imidazo[4,5-c]quinolin-1-yl)propyl]methanesulfonamide
NH
2 N H 0 N.. 5 0 Part A Tert-butyl 3-(2-butyl- 1H-imidazo[4,5-c]quinolin-1-yl)propylcarbamate (-80 g) was dissolved in 1,4-dioxane (400 mL) with gentle heating. Hydrochloric acid (55 mL of 4.0 M in 1,4-dioxane) was added in a single portion and the reaction was heated to reflux. 10 The reaction was monitored by HPLC. Additional acid (150-200 mL) was added and the reaction mixture was refluxed until the reaction was complete. The reaction mixture was cooled to ambient temperature. A solid was isolated by filtration to give -72 g of 3-(2 butyl- 1H-imidazo[4,5-c]quinolin-1-yl)propylamine hydrochloride. This material was combined with that from a previous experiment and then dissolved in water (400 mL). 15 The solution was neutralized with solid potassium carbonate. At pH 7 a solid precipitated. The solid was isolated by filtration and then dissolved in water (1500 mL). The pH was adjusted to pH 10 with solid potassium carbonate. The solution was extracted with chloroform until HPLC analysis showed that no amine remained in the aqueous layer. The organic layers were combined and then concentrated under reduced pressure to provide 45 20 g of 3-(2-butyl- 1H-imidazo[4,5-c]quinolin-1-yl)propylamine. Part B Triethylamine (1.1 g, 10.6 mmol) was added with stirring to a solution of 3-(2 butyl-lH-imidazo[4,5-c]quinolin-1-yl)propylamine (2.00 g, 7.08 mmol) in dichloromethane (-150 mL). Methanesulfonyl chloride (892 mg, 7.79 mmol) was added 25 and the reaction was stirred under nitrogen overnight. The reaction mixture was washed with aqueous 1% sodium bicarbonate solution (3 X 50 mL). The aqueous washes were extracted with dichloromethane (2 x 20 mL). The organics were combined, dried over 26 WO 2005/003065 PCT/US2004/020607 magnesium sulfate and then concentrated under reduced pressure to provide 1.89 g of N [3-(2-butyl-lH-imidazo[4,5-c]quinolin-1-yl)propyl]methanesulfonamide as a light brown solid. Part C 5 Using the general method of Example 2 Part C, the material from Part B was oxidized to provide 1.24 g of N-[3-(2-butyl-5-oxido-1H-imidazo[4,5-c]quinolin-1 yl)propyl]methanesulfonamide. PartD Using the general method of Example 2 Part D, the material from Part C was 10 animated to provide 690 mg of N-[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1 yl)propyl]methanesulfonamide as a light tan solid, m.p. 239.2-240.8 0 C. Analysis: Calculated for C 18
H
25
N
5 0 2 S: %C, 57.58; %H, 6.71; %N, 18.65; Found: %C, 57.37; %H, 6.78; %N, 18.42. 15 Example 9 N-[3-(4-amino-2-butyl 1H-imidazo[4,5-c]quinolin-1-yl)propyl]benzenesulfonamide
NH
2 N N Part A 20 Using the general method of Example 8 Part B, 3-(2-butyl-1H-imidazo[4,5 c]quinolin-1-yl)propylamine (2.00 g, 7.08 mmol) was reacted with benzenesulfonyl chloride (1.38 g, 7.79 mmol) to provide 2.83 g of N-[3-(2-butyl-lH-imidazo[4,5 c]quinolin-1-yl)propyl]benzenesulfonamide as a light red foam. Part B 25 Using the general method of Example 2 Part C, the material from Part A was oxidized to provide 3.28 g of N-[3-(2-butyl-5-oxido-1H-imidazo[4,5-c]quinolin-1 yl)propyl]benzenesulfonamide. 27 WO 2005/003065 PCT/US2004/020607 Part C Using the general method of Example 2 Part D, the material from Part B was animated to provide 1.08 g of N-[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1 yl)propyl]benzenesulfonamide as a light tan solid, m.p. 210.5-212.0oC. Analysis: 5 Calculated for C 23
H
27
N
5 0 2 S: %C, 63.13; %H. 6.22; %N, 16.01; Found: %C, 62.89; %H, 6.16; %N, 15.74. Example 10 N-[4-(4-amino-2-hexyl- IH-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide
NH
2 N 0 HN. 10 0 Part A Using the general method of Example 1, 4-(2-hexyl-1H-imidazo[4,5-c]quinolin-1 yl)butan-1-amine (1.00 g, 3.1 mmol) was reacted with methanesulfonyl choride (0.48 mL, 6.2 mmol) to provide 1.15 g of N-[4-(2-hexyl-l1H-imidazo[4,5-c]quinolin- 1 15 yl)butyl]methanesulfonamide as a white solid. Part B Using the general method of Example 2 Part C, N-[4-(2-hexyl-1H-imidazo[4,5 c]quinolin-1-yl)butyl]methanesulfonamide (1.47 g, 3.7 mmol) was oxidized to provide 3.78 g of crude 1- {4-[(methylsulfonyl)amino]butyl} -2-hexyl-lH-imidazo[4,5-c]quinolin 20 5N-oxide as a yellow residue. Part C Using the general method of Example 2 Part D, the material from Part B was animated to provide 0.28 g of N-[4-(4-amino-2-hexyl-lH-imidazo[4,5-c]quinolin-1 yl)butyl]methanesulfonamide as an off white solid, m.p. 170.2-171.1oC. Analysis: 25 Calculated for C 2 1
H
3 1
N
5 0s 2 S: %C, 60.40; %H, 7.48; %N, 16.77; Found: %C, 59.97; %H, 7.26; %/oN, 16.33. 28 WO 2005/003065 PCT/US2004/020607 Example 11 N-{ 8-[4-amino-2-(2-methoxyethyl)- 1H-imidazo[4,5-c]quinolin-1 yl]octyl} benzenesulfonamide
NH
2 N N 0 H 5 Under a nitrogen atmosphere a solution of 1-(8-aminooctyl)-2-(2-methoxyethyl) 1H-imidazo[4,5-c]quinolin-4-amine (1.0 g, 2.7 mmol) in dichloromethane (50 mL) was cooled to 0OC. Triethylamine (415 pL, 2.98 mmol) was added followed by benzenesulfonyl chloride (345 pL, 2.71 mmol). The reaction mixture was allowed to warm slowly to ambient temperature and then it was maintained overnight. The reaction 10 mixture was washed with water, dried over magnesium sulfate and then concentrated under reduced pressure. The residue was purified by column chromatography (50 g of silica gel eluting with 7.5% methanol in dichloromethane). The purified material was recrystallized from propyl acetate, triturated with hexanes, and then dried in a vacuum oven to provide 590 mg of N- {8-[4-amino-2-(2-methoxyethyl)-lH-imidazo[4,5 15 c]quinolin-l-yl]octyl}benzenesulfonamide as a yellow powder, m.p. 146-149oC. Analysis: Calculated for C 27
H
35
N
5 0sO 3 S: %C, 63.63; %H, 6.92; %N, 13.74; Found: %C, 62.96; %/oH, 7.03; %N, 13.09. Karl Fisher showed 0.16% or 0.045 mole water. 1 H NMR (300 MHz, DMSO-d 6 ) 5 801 (d, J=7.8 Hz, 1H), 7.78 (min, 2H), 7.65-7.55 (min, 5H), 7.45 (min, 1H), 7.28 (m, 1H), 6.71 (s, 2H), 4.50 (min, 2H), 3.83 (min, 2H), 3.5 (broad s, 3H), 20 3.18 (min, 2H), 2.71 (min, 2H), 1.77 (min, 2H), 1.38-1.17 (min, 10H); 3 C NMR (75 MHz, DMSO-d 6 ) 151.7, 151.3, 144.0, 141.0, 132.8, 132.6, 129.5, 127.0, 126.8, 125.9, 121.9, 120.4, 114.9, 70.5, 58.5, 45.3, 42.8, 30.0, 29.2, 28.8, 28.7, 27.5, 26.2, 26.1; MS m/z 510 (M + H). 25 29 WO 2005/003065 PCT/US2004/020607 Example 12 N- {8-[4-amino-2-(2-methoxyethyl)- 1H-imidazo[4,5-c]quinolin-1 yl]octyl} methanesulfonamide
NH
2 N \ O N KO 0
N
11 H ii 0 5 Using the general method of Example 11, 1-(8-aminooctyl)-2-(2-methoxyethyl) 1H-imidazo[4,5-c]quinolin-4-amine (800 mg, 2.17 mmol) was reacted with methanesulfonyl chloride (172 pL, 2.17 mmol) to provide 720 mg of N-{8-[4-amino-2-(2 methoxyethyl)- lH-imidazo[4,5-c]quinolin-1-yl]octyl}methanesulfonamide as a yellow powder, m.p. 109-110 0 C. Analysis: Calculated for C 2 2
H
3 3
N
5 0 3 S: %C, 59.04; %H, 7.43; 10 %N, 15.65; Found: %C, 58.78; %H, 7.38; %N, 15.48. H NMR (300 MHz, DMSO-d 6 ) 8 8.01 (d, J=8.3 Hz, 1H), 7.62 (d, J=8.3 Hz, 1H), 7.42 (inm, 1H), 7.26 (min, 1H), 6.91 (min, 1H), 6.51 (s, 2H), 4.51 (t, J=7.3 Hz, 2H), 3.83 (t, J=6.8 Hz, 2H), 3.34 (s, 3H), 3.18 (t, J=6.8 Hz, 2H), 2.89 (min, 2H), 2.86 (s, 3H), 1.80 (mn, 2H), 1.27 (min, 10H); 15 13 C NMR (125 MHz, DMSO-d 6 ) 152.0, 151.0, 145.0, 132.6, 132.6, 126.7, 126.6, 121.56, 120.3, 115.1, 70.5, 58.5, 45.3, 42.8, 30.0, 29.7, 28.9, 28.8, 27.5, 26.4, 26.2; MS m/z 448 (M+ 1). 30 WO 2005/003065 PCT/US2004/020607 Example 13 N-[8-(4-amino-2-butyl-l1H-imidazo[4,5-c]quinolin-1-yl)octyl]methanesulfonamide
NH
2 N N 0 N-S H i 0 Using the general method of Example 11, 1-(8-aminooctyl)-2-butyl-1H 5 imidazo[4,5-c]quinolin-4-amine (1.2 g, 3.26 mmol) was reacted with methanesulfonyl chloride (260 pL, 3.26 mmol) to provide 0.70 g of N-[8-(4-amino-2-butyl-lH imidazo[4,5-c]quinolin-1-yl)octyl]methanesulfonamide as a tan powder, m.p. 121-124°C. Analysis: Calculated for C 23
H
35
N
5 0sO 3 S: %C, 61.99: %H, 7.92; %N, 15.72; Found: %C, 62.01; %H, 7.97; %N, 15.75. 10 'H NMR (300 MHz, DMSO-d 6 ) 8 8.01 (d, J-8.3 Hz, 1H), 7.61 (dd, J=8.3, 1.0 Hz, 1H), 7.41 (dt, J=8.3 1.5 Hz, 1H), 7.25 (dt, J=8.3, 1.5 Hz, 1H), 6.91 (t, J=4.9 Hz, 1H), 6.47 (s, 2H), 4.48 (t, J=7.3 Hz, 2H), 2.90 (m, 4H), 2.86 (s, 3H), 1.80 (mn, 4H), 1.44 (m, 6H), 1.27 (mn, 6H), 0.96 (t, J=7.3 Hz, 3H); 13 C NMR (500 MHz, DMSO-d 6 ) 153.3, 152.1,145.1,132.5, 126.8. 126.7, 126.6, 121.5, 15 120.2, 115.2, 45.1, 42.8, 39.6, 30.1, 30.0, 29.8, 28.9, 28.8, 26.5, 26.4, 26.2, 22.3, 14.1; MS m/z 446 (M + 1). 31 WO 2005/003065 PCT/US2004/020607 Example 14 N-[3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]-5 (dimethylamino)naphthalene- 1-sulfonamide
NH
2 N NH O= S= O /N" 5 Under a nitrogen atmosphere triethylamine (765 mg, 7.56 mmol) was added to a solution of 1-(3-aminopropyl)-2-butyl-lH-imidazo[4,5-c]quinolin-4-amine (1.5 g, 5.04 mmol) in 1-methyl-2-pyrrolidinone (75 mL). A solution of 5-dimethylamino-1 naphthalenesulfonyl chloride (1.5 g, 5.55 mmol) in 1-methyl-2-pyrrolidinone was added. The reaction was monitored by HPLC. The reaction mixture was combined with water 10 (500 mL) and the pH was adjusted to 10 with solid potassium carbonate. The resulting yellow precipitate was isolated by filtration, rinsed with water and then purified by column chromatography (silica gel eluting with 1 - 5% methanol in chloroform). The purified material was recrystallized from acetonitrile to provide 1.76 g of N-[3-(4-amino-2-butyl 1H-imidazo [4,5-c]quinolin-1-yl)propyl]-5-(dimethylamino)naphthalene-l-sulfonamide as 15 a solid, m.p. 216.5-217.5oC. Analysis: Calculated for C 29
H
34
N
6 0 2 S: %C, 65.64; %H, 6.46; %N, 15.84; Found: %C, 65.52; %H, 6.44; %N, 15.90. 32 WO 2005/003065 PCT/US2004/020607 Example 15 N-[3-(4-amino-2-butyl-IH-imidazo[4,5-c]quinolin-1-yl)propyl]-4 methylbenzenesulfonamide
NH
2 N NH I C=s=O O=S=:O 5 Using the general method of Example 14 1-(3-aminopropyl)-2-butyl-1H imidazo[4,5-c]quinolin-4-amine (1.5 g, 5.04 mmol) was reacted with p-toluenesulfonyl chloride (1.08 g, 5.55 mmol) to provide 1.57 g of N-[3-(4-amino-2-butyl-1H-imidazo[4,5 c]quinolin-1-yl)propyl]-4-methylbenzenesulfonamide as an off white powder, m.p. 197.0 198.5oC. Analysis: Calculated for C 2 4
H
2 9
N
5 0 2 S: %C, 63.83; %H, 6.47; %N, 1551; 10 Found: %C, 63.68; %H, 6.40; %N, 15.51. Example 16 N- {3-[4-amino-2-(2-methoxyethyl) 1H-imidazo[4,5-c]quinolin-1-yl]propyl}methanesulfonamide
NH
2 0 N HO N ,S" 15 O Using the general method of Example 11, 1-(3-aminopropyl)-2-(2-methoxyethyl) 1H-imidazo[4,5-c]quinolin-4-amine (1.53 g, 5.11 mmol) was reacted with methanesulfonyl chloride to provide 800 mg of N- {3-[4-amino-2-(2-methoxyethyl)-1H imidazo[4,5-c]quinolin-1-yl]propyl}methanesulfonamide as light yellow needles, m.p. 33 WO 2005/003065 PCT/US2004/020607 193-194oC. Analysis: Calculated for C 1 7
H
23
N
5 0 3 S: %C, 54.09; %H, 6.14; %N, 18.55; Found: %C, 54.09; %H, 5.93; %N, 18.49. Example 17 5 N-[8-(4-amino-2-butyl- 1H-imidazo[4,5-c]quinolin- 1 -yl)octyl]benzenesulfonamide
NH
2 N 0 11 Using the general method of Example 11, 1-(8-aminooctyl)-2-butyl-1lHimidazo[4,5-c]quinolin-4-amine (1.0 g, 2.72 mmol) was reacted with benzenesulfonyl chloride (350 gL, 2.72 mmol) to provide 1.38 g of N-[8-(4-amino-2-butyl-1H 10 imidazo[4,5-c]quinolin-1-yl)octyl]benzenesulfonamide as an off white powder, m.p. 143 144oC. Analsysis: Calculated for C 2 8
H
3 7
N
5 0sO 2 S: %C, 66.24; %H, 7.35; %N, 13.79; Found: %C, 66.08; %H, 7.25; %N, 13.72. Karl Fisher titration found 0.23% water. 'H NMR (300 MHz, DMSO-d 6 ) 5 7.98 (d, J=7.8 Hz, 1H), 7.77 (mn, 2H), 7.62-7.53 (m, 5H), 7.41 (mn, 1H), 7.25 (min, 1H), 6.47 (s, 2H), 4.47 (m, 2H), 2.90 (min, 2H), 2.70 (q, J=6.3 15 Hz, 2H), 1.78 (min, 4H), 1.49-1.17 (min, 12H), 0.95 (t, J=7.3, 3H); 13C NMR (125 MHz, DMSO-d 6 ) 153.3, 152.0, 145.0, 141.0, 132.5, 129.5, 126.82, 126.76, 126.7, 126.6, 121.5, 120.3, 120.2, 115.1, 45.1, 42.8, 30.0, 29.2, 28.8, 28.7, 26.5, 26.2, 26.1, 22.3, 14.2, 14.1; MS m/z 507 (M + 1). 20 34 WO 2005/003065 PCT/US2004/020607 Example 18 N- {3-[4-amino-2-(2-methoxyethyl) 1H-imidazo[4,5-c]quinolin-1-yl]propyl}benzenesulfonamide
NH
2 N H 0 N 0I 5 Using the general method of Example 11, 1-(3-aminopropyl)-2-(2-methoxyethyl) 1H-imidazo[4,5-c]quinolin-4-amine (1.53 g, 5.11 mmol) was reacted with benzenesulfonyl chloride (993 mg, 5,62 mmol) to provide 1.37 g of N-{3-[4-amino-2-(2 methoxyethyl)- 1H-imidazo[4,5-c]quinolin- 1 -yl]propyl} benzenesulfonamide as a white powder, m.p. 149-151 C. Analysis: Calculated for C 22
H
25
N
5 0 3 S: %C, 60.12; %H, 5.73; 10 %N, 15.93; Found: %C, 60.40; %H, 5.82; %N, 15.85. Example 19 N-[4-(4-amino-2-pentyl 1H-imidazo[4,5-c]quinolin- 1 -yl)butyl]methanesulfonamide
NH
2 N 0 HN., 15 O0 Using the general method of Example 14, 1-(4-aminobutyl)-2-pentyl-1H imidazo[4,5-c]quinolin-4-amine (1.50 g, 4.6 mmol) was reacted with methanesulfonyl chloride (0.57 mL, 7.4 mmol) to provide 636 mg of N-[4-(4-amino-2-pentyl-1H imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide as an off white solid, m.p. 136.8 20 138.1C. Analysis: Calculated for C 20
H
29
N
5 0 2 S: %C, 59.53; %H, 7.24; %N, 17.35; Found: %C, 59.50; %H, 7.31; %N, 16.80. 35 WO 2005/003065 PCT/US2004/020607 Example 20 N-[4-(4-amino-2-pentyl 1H-imidazo[4,5-c]quinolin- 1-yl)butyl]benzenesulfonamide NH 2 N N N O HN, 5 S Using the general method of Example 1, 1-(4-aminobutyl)-2-pentyl-1H imidazo[4,5-c]quinolin-4-amine (1.00 g, 3.1 mmol) was reacted with benzenesulfonyl chloride (0.51 mL, 4.0 mmol) to provide 0.35 g of N-[4-(4-amino-2-pentyl-lH imidazo[4,5-c]quinolin-1-yl)butyl]benzenesulfonamide as a yellow crystalline solid. 10 Analysis: Calculated for C 25
H
3 1
N
5 0 2 S - 0.5 H 2 0: %C, 63.27; %H, 6.80; %/oN, 14.76; Found: %C, 62.99; %H, 6.61; %N, 14.42. Example 21 N-[8-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)octyl]methanesulfonamide
NH
2 N" N O \> N i H-S, 15 O Using the general method of Example 11, 1-(8-aminooctyl)-1H-imidazo[4,5 c]quinolin-4-amine (3.85 mmol) was reacted with methanesulfonyl chloride (310 pL, 3.85 mmol) to provide 0.43 g ofN-{8-[4-amino-lH-imidazo[4,5-c]quinolin-1 yl]octyl}methanesulfonamide as an off white powder, m.p. 153-155C. Analysis: 36 WO 2005/003065 PCT/US2004/020607 Calculated for C 19
H
27
N
5 0 2 S: %C, 58.59; %H, 6.99; %N, 17.98; %S, 8.23; Found: %C, 58.40; %H, 6.99; %N, 17.71; %S, 8.14. 'H NMR (300 MHz, DMSO-d 6 ) 8 8.20 (s, 1H), 8.03 (d, J=7.8 Hz, 1H), 7.63 (d, J=8.3 Hz, 1H), 7.45 (mn, 1H), 7.27 (m, 1H), 6.91 (m, 1H), 6.63 (d, 2H), 4.59 (m, 2H), 2.89 (m, 2H), 5 2.86 (s, 3H), 1.86 (min, 2H), 1.41-1.25 (mn, 10H); 3 "C NMR (125 MHz, DMSO-d 6 ) 152.5, 145.2, 143.2, 132.0, 128.5, 127.1, 126.5, 121.6, 120.8, 115.2, 46.9, 42.8, 39.6, 30.0, 29.7, 28.81, 28.78, 26.4, 26.1; MS m/z 390 (M + 1). 10 Example 22 N- {3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin- 1 -yl]propyl }-4 methylbenzenesulfonamide
NH
2 N H 0 Using the general method of Example 11, 1-(3-aminopropyl)-2-(2-methoxyethyl) 15 1H-imidazo[4,5-c]quinolin-4-amine (1.53 g, 5.11 mmol) was reacted withp toluenesulfonyl chloride (1.07 g, 5,62 mmol) to provide 750 mg of N- {3-[4-amino-2-(2 methoxyethyl)-IH-imidazo[4,5-c]quinolin-1-yl]propyl}-4-methylbenzenesulfonamide as a solid, m.p. 189-191oC. Analysis: Calculated for C 2 3
H
2 7
N
5 0 3 S - 0.50 H 2 0: %C, 59.72; %H, 6.10; %N, 15.14; Found: %C, 59.73; %H, 5.95; %N, 15.08. 20 37 WO 2005/003065 PCT/US2004/020607 Example 23 N-[4-(4-amino-2-pentyl-6,7,8,9-tetrahydro 1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide
NH
2 N\ N N HN
-S
O'\ 5 A solution of 1-(4-aminobutyl)-2-pentyl-6,7,8,9-tetrahydro-lH-imidazo[4,5 c]quinolin-4-amine (1.50 g, 3.7 mmol) in chloroform (150 mL) was chilled in an acetone/ice bath. Methanesulfonic anhydride (0.79 g, 3.7 mmol) was slowly added. After 1.75 hr, 0.018 g of anhydride was added. At 2.5 hrs 0.079 g of anhydride was added. After 3 hrs, the reaction mixture was washed with aqueous 1% sodium carbonate solution 10 (3 X 150 mL). The organic layer was dried over magnesium sulfate and then concentrated under reduced pressure to provide 2.2 g of a light yellow residue. The residue was combined with aqueous 1% sodium carbonate solution (200 mL) and the pH was adjusted to 13 by the addition of solid sodium carbonate and 50% sodium hydroxide. The organic phase was separated, washed with aqueous 1% sodium carbonate solution (3 X 200 mL), 15 dried over magnesium sulfate and then concentrated under reduced pressure to provide 2.18 g of a brown residue. This material was slurried with methyl acetate. The resulting solid was isolated to provide 1.25 g of N-[4-(4-amino-2-pentyl-6,7,8,9-tetrahydro-1H imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide as a white solid, m.p. 167.0 167.8 0 C. Analysis: Calculated for C 2 0
H
3 3
N
5 0sO 2 S: %C, 58.94; %H, 8.16; %N, 17.18; 20 Found: %C, 58.79; %H, 7.92; %/oN, 17.02. 38 WO 2005/003065 PCT/US2004/020607 Example 24 N- {3-[4-amino-2-(ethoxymethyl) 1H-imidazo[4,5-c]quinolin-1-yl]propyl}methanesulfonamide
NH
2 NN H N O Ko H 0 N,. 5 A mixture of 1 -(3-aminopropyl)-2-(ethoxymethyl)- 1H-imidazo[4,5-c]quinolin-4 amine (2.0 g, 6.7 mmol), triethylamine (1.5 mL, 15 mmol) and acetonitrile (75 mL) was heated until a solution was obtained. Methanesulfonic anhydride (1.28 g, 7.4 mmol) was added in a single portion. After 5 minutes a small amount of anhydride was added. The reaction mixture was allowed to stir overnight. The reaction mixture was quenched with 10 aqueous 1% sodium carbonate solution. The aqueous layer was extracted with chloroform. The organics were dried over magnesium sulfate, filtered and then concentrated under reduced pressure. The residue was dried under high vacuum for 3 hours to provide 2.73 g of a glassy solid. This material was recrystallized from methanol to provide 1.38 g of N- {3-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1 15 yl]propyl}methanesulfonamide, m.p. 208.2-209.6oC. Analysis: Calculated for Cl7H 23
N
5 0 3 S: %C, 54.09; %H, 6.14; %N, 18.55; Found: %C, 53.97; %H, 6.29; %/oN, 18.32. 39 WO 2005/003065 PCT/US2004/020607 Example 25 N- {3-[4-amino-2-(2-methoxyethyl) 1H-imidazo[4,5-c]quinolin-1l-yl]-2,2-dimethylpropyl}methanesulfonamide
NH
2 N N\ O N NH O=S=O 5 Using the general method of Example 11, 1-(3-amino-2,2-dimethylpropyl)-2-(2 methoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine (0.22 g, 0.672 mmol) was reacted with methanesulfonyl chloride (125 pL) to provide 270 mg of N-{3-[4-amino-2-(2 methoxyethyl)-l1H-imidazo[4,5-c]quinolin-1-yl]-2,2-dimethylpropyl} methanesulfonamide as a cream colored powder, m.p. 204.0-206.0 0 C. Analysis: Calculated for C 19
H
27
N
5 0 3 S ' 10 0.50 H 2 0: %C, 55.05; %H, 6.81; %N, 16.89; %S, 7.74; Found: %C, 55.10; %H, 6.58; %N, 17.23; %S, 7.51. % H 2 0 calculated: 2.17; found: 2.28 (Karl Fisher). 1 H NMR (300 MHz, DMSO-d 6 ) 6 8.36 (d, J=8.3 Hz, 1H), 7.59 (d, J=8.3 Hz, 1H), 7.38 (inm, 2H), 7.20 (min, 1H), 6.49 (s, 2H), 4.81 (br s, 1H), 4.39 (br s, 1H), 3.82 (min, 2H), 3.27 (s, 3H), 3.19 (br s, 2H), 3.02 (d, J=6.8 Hz, 2H), 2.94 (s, 3H), 0.82 (br s, 6H); 15 13C NMR (125 MHz, DMSO-d 6 ) 8 152.5, 152.0, 145.3, 133.9, 126.8, 126.7, 126.6, 121.5, 120.7, 115.8, 71.0, 58.5, 51.8, 51.5, 39.7, 39.0, 28.3, 24.4, 23.1; MS m/z 406 (M + H). 40 WO 2005/003065 PCT/US2004/020607 Example 26 N- {3-[4-amino-2-(2-methoxyethyl)- 1H-imidazo[4,5-c]quinolin- 1 -yl]propyl } 5-(dimethylamino)naphthalene- 1-sulfonamide
NH
2 N N O1 N HO0
N,
/ 6 N I 5 Using the general method of Example 14 except that chloroform was used as the solvent, 1-(3-aminopropyl)-2-(methoxyethyl)-1H-imidazo[4,5-c]quinolin-4-amine (1.53 g, 5.11 mmol) was reacted with 5-dimethylamino-1-naphthalenesulfonyl chloride (5.87 mmol) to provide 1.45 g of N- {3-[4-amino-2-(2-methoxyethyl)- 1H-imidazo[4,5 c]quinolin-1-yl]propyl} -5-(dimethylamino)naphthalene-l1-sulfonamide as a yellow solid, 10 m.p. 210-215oC. Analysis: Calculated for C 2 8
H
3 2
N
6 0 3 S " 1.50 H 2 0: %C, 60.09; %H, 6.30; %N, 15.02; Found: %C, 59.89; %H, 6.22; %/oN, 14.86. Example 27 N-[3-(4-amino-2-methyl 15 1H-imidazo[4,5-c]quinolin-1-yl)propyl]methanesulfonamide
NH
2 N N N 0 Using the general method of Example 24, 1-(3-aminopropyl)-2-methyl-1H imidazo[4,5-cjquinolin-4-aminc (2.0 g, 7.8 mmol) was reacted with methanesulfonic anhydride (1.49 g, 8.6 mmol) to provide 1.2 g of N-[3-(4-amino-2-methyl-1H 20 imidazo[4,5-c]quinolin-1-yl)propyl]methanesulfonamide as a solid, m.p. 236.0-238.0oC. 41 WO 2005/003065 PCT/US2004/020607 Analysis: Calculated for C 1 5
H
19
N
5 0 2 S -0.25 H 2 0: %C, 53.32; %H, 5.82; %N, 20.72; Found: %C, 53.35; %H, 5.72; %N, 20.57. Example 28 5 N- {3-[4-amino-2-(2-methoxyethyl)-6,7,8,9-tetrahydro 1H-imidazo[4,5-c]quinolin-1-yl]propyl}methanesulfonamide
NH
2 N
H
0 N H0 Using the general method of Example 24, 1-(3-aminopropyl)-2-(2-methoxyethyl) 6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-4-amine (2.0 g, 6.6 mmol) was reacted with 10 methanesulfonic anhydride (1.26 g, 7.3 mmol) to provide 630 mg ofN-{3-[4-amino-2-(2 methoxyethyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-1 yl]propyl}methanesulfonamide as a solid, m.p. 150.0-152.0 0 C. Analysis: Calculated for
C
17
H
27
N
5 0 3 S: %C, 53.52; %H, 7.13; %N, 18.36; Found: %C, 53.27; %H, 7.12; %N, 18.37. 15 Example 29 N- {3-[4-amino-2-(ethoxymethyl)-6,7,8,9-tetrahydro 1H-imidazo[4,5-c]quinolin- 1 -yl]propyl } methanesulfonamide
NH
2 N
H
0 Ns 0 20 Using the general method of Example 24, except that chloroform was used in place of aceotnitrile, 1-(3-aminopropyl)-2-(2-ethoxymethyl)-6,7,8,9-tetrahydro- 1H-imidazo[4,5 c]quinolin-4-amine (2.6 g, 8.35 mmol) was reacted with methanesulfonic anhydride (3+ g) 42 WO 2005/003065 PCT/US2004/020607 to provide 850 mg of N- {3-[4-amino-2-(2-ethoxymethyl)-6,7,8,9-tetrahydro-1H imidazo[4,5-c]quinolin-1-yl]propyl} methanesulfonamide as a solid, m.p. 212.0-214.0 0 C. Analysis: Calculated for C 1 7
H
27
N
5 0 3 S: %C, 53.52; %H, 7.13; %N, 18.36; Found: %C, 53.25; %H, 7.16; %N, 18.09. 5 Example 30 N- {3-[4-amino-2-(3-phenoxypropyl) 1H-imidazo[4,5-c]quinolin-1 -yl]propyl}methanesulfonamide
NH
2 N H0 N, ' 0 10 Using the general method of Example 11, except that chloroform was used in place of dichloromethane, 1-(3-aminopropyl)-2-(3-phenoxypropyl)- 1H-imidazo[4,5-c]quinolin 4-amine (2.00 g, 5.32 mmol) was reacted with methanesulfonyl chloride (3+ g) to provide 1.38 g of N- {3-[4-amino-2-(3-phenoxypropyl)- 1H-imidazo[4,5-c]quinolin- 1 yl]propyl}methanesulfonamide as a solid, m.p. 176-178oC. Analysis: Calculated for 15 C 2 3
H
2 7
N
5 0 3 S: %C, 60.91; %H, 6.00; %N, 15.44; Found: %C, 60.71; %H, 5.98; %N, 15.45. 43 WO 2005/003065 PCT/US2004/020607 Example 31 N- { 4 -[4-amino-2-(3-phenoxypropyl) 1H-imidazo[4,5-c]quinolin- 1 -yl]butyl } methanesulfonamide
NH
2 N NH
V
0 5 Using the general method of Example 24, except that pyridine was used in place of acetonitrile, 1-(3-aminobutyl)-2-(3-phenoxypropyl)- lH-imidazo[4,5-c]quinolin-4-amine (2.00 g, 5.1 mmol) was reacted with an excess of methanesulfonic anhydride to provide 1.36 g of N- { 4
-[
4 -amino-2-(3-phenoxypropyl)-1H-imidazo[4,5-c]quinolin-1 yl]butyl}methanesulfonamide as a solid, m.p. 156.4-157.1IC. Analysis: Calculated for 10 C 2 4
H
2 9
N
5 0 3 S: %C, 60.48; %H, 6.34; %N, 14.69; Found: %C, 60.75; %H, 6.36; %N, 14.31. Example 32
N-[
4
-(
4 -amino-2-methyl-6,7,8,9-tetrahydro 15 1H-imidazo[4,5-c]quinolin- 1-yl)butyl]methanesulfonamide hydrochloride
NH
2 N\ N HN HN 0
S
0 \ Using the general method of Example 23, 1-(4-aminobutyl)-2-methyl-6,7,8,9 tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine (1.00 g, 3.7 mmol) was reacted with methanesulfonic anhydride (0.96 g, 5.5 mmol) in the presence of triethylamine (0.76 mL, 20 5.5 mmol) to provide 0.55 g of the free base of the desired product. This material was combined with methanol (-20 mL), warmed, allowed to cool to ambient temperature and 44 WO 2005/003065 PCT/US2004/020607 then filtered to remove some insoluble material. The filtrate was reduced to a volume of -10 mL and then combined with IN hydrochloric acid (3 mL). Diethyl ether (15 mL) was added and then the mixture was concentrated under reduced pressure. The resulting residue was slurried with isopropyl alcohol to provide a white solid which was isolated by 5 filtration and then dried to provide 0.46 g of N-[4-(4-amino-2-methyl-6,7,8,9-tetrahydro 1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide hydrochloride, m.p. >250 0 C. Analysis: Calculated for C 1 6
H
25
N
5 0 2 S ' 1.00 HCI - 1.00 H 2 0: %C, 47.34; %H, 6.95; %N, 17.25; Found: %C, 47.40; %H, 6.49; %N, 17.22. 10 Example 33 N-[2-(4-amino-2-butyl- 1H-imidazo[4,5-c]quinolin- 1 -yl)ethyl]-4 methylbenzenesulfonamide
NH
2 N NH I O= S= O Triethylamine (1.1 g, 15.9 mmol) was added to a cooled (0 0 C) solution of 1-(2 15 aminoethyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine (3.0 g, 10.6 mmol) in 1-methyl 2-pyrrolidinone (100 mL). A solution of tosyl chloride (2.11 g, 11.1 mmol) in 1-methyl-2 pyrrolidinone (20 mL) was slowly added in a dropwise fashion. The reaction was allowed to warm to ambient temperature and was maintained overnight. The reaction was poured into water (1500 mL) and adjusted to pH 9. A white precipitate was isolated by filtration 20 and then recrystallized from acetonitrile (60 mL) to provide 3.9 g of N-[2-(4-amino-2 butyl-lH-imidazo[4,5-c]quinolin-1-yl)ethyl]-4-methylbenzenesulfonamide, m.p. 187.0 188.0oC. Analysis: Calculated for C 23
H
27
N
5 0 2 S - 0.3 H 2 0: %C, 62.29; %H, 6.28; %N, 15.79; Found: %C, 62.52; %H, 6.36; %N, 15.88. 45 WO 2005/003065 PCT/US2004/020607 Example 34 N-[2-(4-amino-2-butyl- 1H-imidazo[4,5-c]quinolin- 1 -yl)ethyl]methanesulfonamide
NH
2 N NH o=s=o I Methanesulfonyl chloride (1.27 g, 11.1 mmol) was slowly added to a solution of 1 5 ( 2 -aminoethyl)-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine (3.0 g, 10.6 mmol) in pyridine (60 mL). The reaction was maintained at ambient temperature overnight and then it was concentrated to dryness. The residue was combined with warm dichloroethane and water and then filtered to provide an off white solid. The dichloroethane layer was concentrated to provide an off white solid. The two solids were combined and then recrystallized from 10 N,N-dimethylformamide to provide 1.1 g of N-[2-(4-amino-2-butyl-lH-imidazo[4,5 c]quinolin-1-yl)ethyl]methanesulfonamide as a white solid, m.p. 210.0-211.0C. Analysis: Calculated for C 17
H
2 3
N
5 0 2 S: %C, 56.49; %H, 6.41; %N, 19.37; Found: %C, 56.45; %H, 6.49; %N, 19.50. 15 Example 35 1-[4-( 1,1 -dioxidoisothiazolidin-2-yl)butyl]-2-(2-methoxyethyl) 1H-imidazo[4,5-c]quinolin-4-amine
NH
2 N 0 NO1 S' U 0 Under a nitrogen atmosphere, 1-(4-aminobutyl)-2-(2-methoxyethyl)-1H 20 imidazo[4,5-c]quinolin-4-amine (500 mg, 1.6 mmol) was dissolved in dichloromethane (5 mL) and triethylamine (0.33 mL, 2.4 mmol). 3-Chloropropylsulfonyl chloride (0.19 mL, 1.6 mmol) was added dropwise and the reaction was stirred for 2 hours. The solvent was 46 WO 2005/003065 PCT/US2004/020607 removed in vacuo. The residue was dissolved in N,N-dimethylformamide (5 mL) and 1,8 diazabicyclo[5.4.0]undec-7-ene (0.48 mL, 3.2 mmol) was added. The reaction was stirred for 72 hours and then poured into water and extracted with dichloromethane. The organic layer was washed with water followed by brine; dried (Na 2
SO
4 ); decanted and evaporated 5 to yield crude product as a brown oil. Purification involved flash column chromatography (silica gel, gradient elution with methanol /dichloromethane 100:0 to 94:6) followed by recrystallization from acetonitrile to provide 289 mg of 1-[4-(1,1-dioxidoisothiazolidin-2 yl)butyl]-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-4-amine as a yellow crystalline solid, m.p. 156.4-157.7 C. 10 'H-NMR (500MHz, DMSO-d 6 ) 6 8.04 (d, J = 7.4 Hz, 1H), 7.62 (dd, J = 8.3, 1.2 Hz, 1H); 7.42 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.26 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 6.48 (bs, 2H), 4.54 (t, J = 7.6 Hz, 2H), 3.84 (t, J = 6.7 Hz, 2H), 3.29 (s, 3H), 3.22-3.12 (min, 6H), 2.93 (t, J = 6.6 Hz, 2H), 2.23-2.13 (min, 2H), 1.90-1.65 (m, 4H); 1 3 C-NMR (125MHz, DMSO-d 6 ) 6151.6, 150.6, 144.8, 132.2, 126.5, 126.3, 121.2, 120.0, 15 114.7, 70.2, 58.1, 46.5, 46.1, 44.5, 43.6, 27.1, 24.1, 18.3; Anal calcd for C 2 0
H
2 7
N
5 0 3 S: %C, 57.53; %H, 6.52; %N, 16.77; %S, 7.68. Found: %C, 57.52; %H, 6.67; %N, 16.88; %S, 7.71. Example 36 20 2-butyl- 1 -[4-(1,1-dioxidoisothiazolidin-2-yl)butyl] 1H-imidazo[4,5-c]quinolin-4-amine
NH
2 N N N N-S=O Using the general method of Example 35 except that 1-methyl-2-pyrrolidinone was used in place of dichloromethane, 1-(4-aminobutyl)-2-butyl- 1H-imidazo[4,5-c]quinolin-4 25 amine (5.0 g, 16.0 mmol) was reacted with 3-chloropropanesulfonyl choride (2.83 g, 16.0 47 WO 2005/003065 PCT/US2004/020607 mmol) to provide 0.75 g of 2-butyl-l-[4-(1,1-dioxidoisothiazolidin-2-yl)butyl]-1H imidazo[4,5-c]quinolin-4-amine as a white solid, m.p. 173.0-176.0oC. 1 H-NMR (300 MHz, DMSO-d 6 ) 6 8.30 (d, J = 8.1 Hz, IH), 7.62 (d, J = 8.2 Hz, 1H), 7.41 (t, J = 7.6 Hz, 1H), 7.26 (t, J = 8.0 Hz, 1H), 6.48 (bs, 2H), 4.51 (t, J = 7.5 Hz, 2H), 3.18 5 3.11 (m, 4H), 2.96-2.89 (m, 4H), 2.22-2.12 (min, 2H), 1.92-1.63 (m, 6H), 1.45 (sextet, J = 7.4 Hz, 2H), 0.96 (t, J = 7.3 Hz, 3H); 1 3 C-NMR (75 MHz, DMSO-d 6 ) 153.0,151.7,144.7, 132.2, 126.4, 126.2, 121.1,120.0, 114.7, 46.5, 46.1, 44.3, 43.6, 29.7, 27.1, 26.1, 24.1, 22.0, 18.3, 13.8; MS (CI) m/e 416.2124 (416.2120 calcd for C 2 1
H
3 0
N
5 0 2 S, M+H); 10 Anal calcd for C 2 1
H
29
N
5 0 2 S: %C, 60.70; %H, 7.03; %N, 16.85; %S, 7.72. Found: %C, 60.67; %H, 6.94; %/oN, 17.02; %S, 7.42. Example 37 N- {2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1 15 dimethylethyl} methanesulfonamide
NH
2 N N 'o N 0 HN, 0 Part A A stirred solution of 4-chloro-3-nitroquinoline (17.3 g, 83.2 mmol) in 200 mL of anhydrous CH 2 C1 2 , under N 2 , was treated with triethylamine (23.2 mL, 166.4 mmol) and 20 1,2-diamino-2-methylpropane (9.57 mL, 91.5 mmol). After stirring overnight, the reaction mixture was diluted with 800 mL of CHC1 3 washed with H 2 0 (3 X 300 mL) and brine (300 mL). The organic portion was dried over Na 2
SO
4 and concentrated to give 2 methyl-N -(3-nitroquinolin-4-yl)propane-1,2-diamine (21.0 g) as a bright yellow solid. Part B 25 A solution of 2-methyl-N'-(3-nitroquinolin-4-yl)propane-1,2-diamine (2.60 g, 10.0 mmol) in 50 mL of THF, under N 2 , was cooled to 0 oC and treated with 10 mL of 1N NaOH solution. Di-tert-butyl dicarbonate (2.18 g, 10.0 mmol) was then added to the 48 WO 2005/003065 PCT/US2004/020607 rapidly stirred solution. The reaction mixture was then allowed to warm to ambient temperature and was stirred overnight. An additional 400 mg of di-tert-butyl dicarbonate was added and stirring was continued for 3 d. The reaction was then treated with ethyl acetate (200 mL) and washed with H20 (2X) and brine. The organic portion was dried 5 over Na 2
SO
4 and concentrated to give a yellow solid that was titurated with 10% EtOAc/hexanes. The solid was isolated by filtration and dried under vacuum overnight to give tert-butyl 1,1-dimethyl-2-[(3-nitroquinolin-4-yl)amino]ethylcarbamate (2.80 g) as a yellow powder. Part C 10 A solution of tert-butyl 1,1-dimethyl-2-[(3-nitroquinolin-4 yl)amino]ethylcarbamate (3.50 g, 9.72 mmol), in 150 mL of toluene was treated with 0.3 g of 5% Pt on carbon and shaken under H2 (3 atm, 3 Kg/cm 2 ) for 6 h. The solution was then filtered through a Celite pad and concentrated to give 3.04 g of crude tert-butyl 2-[(3 aminoquinolin-4-yl]-1,1-dimethylethylcarbamate as a light orange foam. 15 Part D A solution of tert-butyl 2-[(3-aminoquinolin-4-yl]-1,1-dimethylethylcarbamate (3.04 g, 9.21 mmol) in 50 mL of CH 2
C
2 was cooled to 0 'C and treated with triethylamine (1.41 mL, 10.13 mmol) and ethoxyacetyl chloride (1.02 mL, 10.17 mmol). After 2 h, the reaction mixture was concentrated under reduced pressure. The resulting syrup was taken 20 up in 100 mL of EtOH and treated with 4.5 mL of triethylamine. The solution was heated to reflux overnight. The reaction mixture was concentrated and taken up in 100 mL of
CH
2
C
2 and washed with H 2 0 (2X) and brine. The organic portion was dried over Na 2
SO
4 and concetrated. The resulting syrup was purified by column chromatography (SiO 2 , 80% EtOAc/hexanes) to give tert-butyl 2-[2-(ethoxymethy)-l1H-imidazo[4,5-c]quinolin-1-yl] 25 1,1-dimethylethylcarbamate (1.57 g) as a peach colored foam. Part E A solution of tert-butyl 2-[2-(ethoxymethy)-lH-imidazo[4,5-c]quinolin-1-yl]-1,1 dimethylethylcarbamate (1.57 g, 3.94 mmol) in 30 mL of CH 2
CI
2 was treated with 3 chloroperoxybenzoic acid (77%, 1.01 g, 4.57 mmol). After stirring for 2 h, the reaction 30 mixture was treated with 30 mL of additional CH 2 Cl 2 and was washed with 1% Na 2
CO
3 solution (2 X 30 mL), H20 and brine. The organic portion was then dried over Na 2
SO
4 and 49 WO 2005/003065 PCT/US2004/020607 concentrated to give tert-butyl 2-[2-(2-(ethoxymethyl)-5-oxido-1H-imidazo[4,5 c]quinolin-1l-yl]-1,1-dimethylethylcarbamate (1.58 g) as a light brown foam. Part F A solution of tert-butyl 2-[2-(2-(ethoxymethyl)-5-oxido-1H-imidazo[4,5 5 c]quinolin-1-yl]-1,1-dimethylethylcarbamate (1.57 g, 3.79 mmol) in 20 mL of 1,2 dichloroethane was heated to 70 'C and treated with 2 mL of concentrated NH 4 OH solution. To the rapidly stirred solution was added solid p-toluenesulfonyl chloride (795 mg, 4.17 mmol). The reaction mixture was then sealed in a pressure vessel and heating was continued for 2 h. The reaction mixture was then cooled and treated with 50 mL of 10 CHC1 3 . The reaction mixture was then washed with H 2 0, 1% Na 2
CO
3 solution (3X) and brine. The organic portion was dried over Na 2
SO
4 and concentrated to give the product as a light brown oil. The resulting oil was purified by column chromatography (SiO 2 , 2-5% MeOH/CHCl 3 ) to give tert-butyl 2-[4-amino-2-(ethoxymethyl)-l1H-imidazo[4,5 c]quinolin-1-yl]-1,1-dimethylethylcarbamate (1.26 g) as a light yellow foam. 15 Part G Tert-butyl 2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]- 1,1 dimethylethylcarbamate (1.26 g, 3.05 mmol) was dissolved in 10 mL of EtOH and treated with 10 mL of 2 M HC1 in EtOH. After heating at reflux for 2 h, the reaction mixture was cooled and concentrated under reduced pressure. The resulting yellow solid was dissolved 20 in 50 mL of H 2 0 and extracted with CHC1 3 (20 mL). The organic layer was discarded and the aqueous portion was made basic (pH - 12) by addition of concentrated NH 4 OH solution. This was then extracted with CHCl 3 (4 x 20 mL) and the combined organic portions were dried with Na 2
SO
4 and concentrated to give 1-(2-amino-2-methylpropyl)-2 (ethoxymethyl)-lH-imidazo[4,5-c]quinoline-4-amine (808 mg) as a light brown powder. 25 m.p. 161.0-162.0 'C; MS m/z 314 (M + H); IH NMR (300 MHz, d 6 -DMSO) 8 8.30 (d, J = 7.7 Hz, 1H), 7.59 (dd, J = 1.2, 8.3 Hz, 1H), 7.40 (ddd, J = 1.0, 7.2, 8.1 Hz, 1H), 7.21 (ddd, J = 1.2, 7.0, 8.2 Hz, 1H), 6.57 (s, 2H), 4.94 (br s, 2H), 4.61 (br s, 2H), 3.52 (q, J = 7.0 Hz, 2H), 1.61 (s, 2H), 1.31 (t, J = 7.0 Hz, 3H), 30 1.07 (s, 6H); 13 C NMR (75 MHz, d 6 -DMSO) 8 152.4, 151.1, 145.7, 134.3, 126.8, 126.7, 121.7, 120.8, 115.7, 65.6, 65.2, 55.8, 52.5, 29.2, 15.4. 50 WO 2005/003065 PCT/US2004/020607 Anal. Called for C 17
H
2 3
N
5 0: %C, 65.15; %H, 7.40; %N, 22.35. Found: %C, 65.04; %H, 7.52; %N, 22.07. Part H 1-(2-Amino-2-methylpropyl)-2-(ethoxymethyl)- 1H-imidazo[4,5-c]quinoline-4 5 amine (111 mg, 0.355 mmol) was dissolved in 5 mL of anhydrous CH 2
C
2 and cooled to 0 oC under N 2 . To the stirred solution were added Et 3 N (99 tL, 0.71 mmol) and methanesulfonyl chloride (28 gL, 0.36 mmol) and the reaction was allowed to warm to ambient temperature overnight. The reaction mixture was then quenched by addition of saturated NaHCO 3 solution (5 mL). The organic layer was separated and washed with 10 H 2 0 (2 X 5 mL) and brine, dried over Na 2
SO
4 and concentrated under reduced pressure to give a tan foam. Purification by column chromatography (SiO 2 , 2.5%-5% MeOH/CHC1 3 ) gave N- {2-[4-amino-2-(ethoxymethyl)- 1H-imidazo[4,5-c]quinolin-1-yl]-1,1 dimethylethyl}methanesulfonamide (75 mg) as a white foam. m..p. 105.0-110.0 oC; 15 MS m/z 392 (M + H)+; 'H NMR (300 MHz, CDC1 3 ) 8 8.06 (dd, J = 1.0, 8.3 Hz, 1H), 7.79 (dd, J = 1.1, 8.4 Hz, 1H), 7.51 (ddd, J = 1.3, 7.0, 8.4 Hz, 1H), 7.31 (ddd, J = 1.3, 7.0, 8.3 Hz, 1H), 5.90 (br s, 1H), 5.51 (br s, 2H), 4.96 (s, 2H), 4.92 (br s, 2H), 3.74 (q, J= 7.0 Hz, 2H), 3.02 (s, 3H), 1.55 (br s, 6H), 1.29 (t, J = 7.0 Hz, 3H); 20 " 3 C NMR (75 MHz, CDCl 3 ) 6 152.0, 150.8, 145.5, 135.2, 127.8, 127.6, 127.2, 122.2, 120.6, 116.0, 67.2, 65.4, 58.4, 55.8, 45.3, 26.6, 15.3. Anal. Called for C 18
H
25
N
5 0 3 S*0.75H 2 0: C, 53.38; %H, 6.60; %N, 17.29. Found: %C, 53.49; %H, 6.23; %N, 16.93. 51 WO 2005/003065 PCT/US2004/020607 Example 38 N-[4-(4-amino-2-methyl- lH-imidazo[4,5-c]quinolin-1 -yl)butyl]ethanesulfonamide
NH
2 N 0 HIt 0 Using the general method of Example 1, 1-(4-aminobutyl)-2-methyl-1H 5 imidazo[4,5-c]quinolin-4-amine (1.00 g, 3.7 mmol) was reacted with ethanesulfonyl chloride (2.11 mL, 22.3 mmol) to provide 85 mg of N-[4-(4-amino-2-methyl-1H imidazo[4,5-c]quinolin-1-yl)butyl]ethanesulfonamide as an off-white solid, m.p. 210.7 211.6 0 C. 10 Example 39 N- {4-[4-amino-2-(cyclopropylmethyl)- 1H-imidazo[4,5-c]quinolin- 1 yl]butyl} methanesulfonamide
NH
2 N 0 N-S, H It 0 Using the general method of Example 38 Part B except that chloroform was used 15 instead of dichloromethane, 1-(4-aminobutyl)-2-(cyclopropylmethyl)-1H-imidazo[4,5 c]quinolin-4-amine (1.00 g, 3.2 mmol) was reacted with methanesulfonic anhydride (1.29 g, 7.4 mmol) to provide 0.42 g of N-{4-[4-amino-2-(cyclopropylmethyl)-I H-imidazo[4,5 c]quinolin-1-yl]butyl}methanesulfonamide as a brown solid, m.p. 199.7-200.7oC. 20 52 WO 2005/003065 PCT/US2004/020607 CYTOKINE INDUCTION IN HUMAN CELLS An in vitro human blood cell system was used to assess cytokine induction by compounds of the invention. Activity is based on the measurement of interferon and tumor necrosis factor (a) (IFN and TNF, respectively) secreted into culture media as 5 described by Testerman et. al. In "Cytokine Induction by the Immunomodulators Imiquimod and S-27609", Journal of Leukocyte Biology, 58, 365-372 (September, 1995). Blood Cell Preparation for Culture Whole blood is collected by venipuncture into EDTA vacutainer tubes from 10 healthy human donors. Peripheral blood mononuclear cells (PBMCs) are separated from whole blood by density gradient centrifugation using Histopaque®-1077 (Sigma Chemicals, St. Louis, MO). The PBMCs are suspended at 3-4 x 106 cells/mL in RPMI 1640 medium containing 10 % fetal bovine serum, 2 mM L-glutamine and 1% penicillin/streptomycin solution (RPMI complete). The PBMC suspension is added to 48 15 well flat bottom sterile tissue culture plates (Costar, Cambridge, MA or Becton Dickinson Labware, Lincoln Park, NJ) containing an equal volume of RPMI complete media containing test compound. Compound Preparation 20 The compounds are solubilized in dimethyl sulfoxide (DMSO). The DMSO concentration should not exceed a final concentration of 1% for addition to the culture wells. Incubation 25 The solution of test compound is added at 60 gM to the first well containing RPMI complete and serial (three fold or ten fold) dilutions are made. The PBMC suspension is then added to the wells in an equal volume, bringing the test compound concentrations to the desired range. The final concentration of PBMC suspension is 1.5-2 X 106 cells/mL. The plates are covered with sterile plastic lids, mixed gently and then incubated for 18 to 30 24 hours at 37 0 C in a 5% carbon dioxide atmosphere. 53 WO 2005/003065 PCT/US2004/020607 Separation Following incubation the plates are centrifuged for 5-10 minutes at 1000 rpm (-200 x g) at 4oC. The cell culture supematant is removed with a sterile polypropylene pipet and transferred to sterile polypropylene tubes. Samples are maintained at -30 to 5 70 0 C until analysis. The samples are analyzed for interferon (a) and tumor necrosis factor (a) by ELISA Interferon (a) and Tumor Necrosis Factor (a) Analysis by ELISA Interferon (a) concentration is determined by ELISA using a Human Multi-Species 10 kit from PBL Biomedical Laboratories, New Brunswick, NJ. Tumor necrosis factor (a) (TNF)concentration is determined using ELISA kits available from Genzyme, Cambridge, MA; R&D Systems, Minneapolis, MN; or Pharmingen, San Diego, CA. 15 The table below lists the lowest concentration found to induce interferon and the lowest concentration found to induce tumor necrosis factor for each compound. A "**" indicates that no induction was seen at any of the tested concentrations (0.12, 0.37, 1.11, 3.33, 10 and 30 I.M). A "***" indicates that no induction was seen at any of the tested concentrations (0.0001, 0.001, 0.01, 0.1, 1 and 10 pM). 20 Cytokine Induction in Human Cells Example Lowest Effective Concentration (pM) Number Interferon Tumor Necrosis Factor 1 0.12 1.11 2 0.37 1.11 3 1.11 1.11 4 0.04 1.11 5 0.01 0.12 6 0.37 0.04 7 0.04 0.37 8 0.01 1.11 9 0.37 3.33 54 WO 2005/003065 PCT/US2004/020607 Cytokine Induction in Human Cells Example Lowest Effective Concentration (tM) Number Interferon Tumor Necrosis Factor 10 0.12 1.11 11 0.01 0.01 12 0.01 0.01 13 0.01 0.01 14 3.33 ** 15 1.11 3.33 16 0.01 0.01 17 0.12 0.01 18 0.01 1.11 19 0.01 0.12 20 0.12 10 21 0.37 1.11 22 0.04 0.12 23 0.01 1.11 24 0.12 3.33 25 0.01 0.04 26 1.11 3.33 27 0.37 10 28 0.01 10 29 0.01 0.37 30 ** 10 31 ** 10 32 0.12 ** 33 1.11 1.11 34 0.01 0.04 36 0.01 0.12 37 0.04 0.12 55 WO 2005/003065 PCT/US2004/020607 The present invention has been described with reference to several embodiments thereof. The foregoing detailed description and examples have been provided for clarity of understanding only, and no unnecessary limitations are to be understood therefrom. It will be apparent to those skilled in the art that many changes can be made to the described 5 embodiments without departing from the spirit and scope of the invention. Thus, the scope of the invention should not be limited to the exact details of the compositions and structures described herein, but rather by the language of the claims that follow. 56
Claims (5)
1. N- {2-[4-amino-2-(ethoxymethyl)- 1H-imidazo[4,5-c]quinolin-1-yl] -1,1 dimethylethyl} methanesulfonamide, or a pharmaceutically acceptable salt thereof. 5
2. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 and a pharmaceutically acceptable carrier.
3. A method of inducing cytokine biosynthesis in an animal comprising administering 10 an effective amount of a compound or salt of claim 1 to the animal.
4. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal. 15
5. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal. 57
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48320003P | 2003-06-27 | 2003-06-27 | |
| US60/483,200 | 2003-06-27 | ||
| PCT/US2004/020607 WO2005003065A2 (en) | 2003-06-27 | 2004-06-25 | Sulfonamide substituted imidazoquinolines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2004253929A1 true AU2004253929A1 (en) | 2005-01-13 |
Family
ID=33563911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004253929A Abandoned AU2004253929A1 (en) | 2003-06-27 | 2004-06-25 | Sulfonamide substituted imidazoquinolines |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1638566A4 (en) |
| JP (1) | JP2007521280A (en) |
| KR (1) | KR20060035637A (en) |
| CN (1) | CN1812789B (en) |
| AR (2) | AR044923A1 (en) |
| AU (1) | AU2004253929A1 (en) |
| BR (1) | BRPI0411916A (en) |
| CA (1) | CA2529322A1 (en) |
| IL (1) | IL172427A0 (en) |
| MX (1) | MXPA06000144A (en) |
| MY (1) | MY157827A (en) |
| NZ (1) | NZ544330A (en) |
| RU (1) | RU2374246C2 (en) |
| TW (2) | TW200514784A (en) |
| WO (2) | WO2005003064A2 (en) |
| ZA (1) | ZA200600769B (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040265351A1 (en) | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
| JP2007502288A (en) | 2003-08-12 | 2007-02-08 | スリーエム イノベイティブ プロパティズ カンパニー | Oxime-substituted imidazo-containing compounds |
| AU2004268625B2 (en) | 2003-08-27 | 2011-03-31 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
| CA2537763A1 (en) | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
| ES2584863T3 (en) | 2003-10-03 | 2016-09-29 | 3M Innovative Properties Company | Pyrazolopyridines and analogues thereof |
| WO2005032484A2 (en) | 2003-10-03 | 2005-04-14 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
| US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| CA2545825A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
| JP2007511527A (en) | 2003-11-14 | 2007-05-10 | スリーエム イノベイティブ プロパティズ カンパニー | Oxime-substituted imidazo ring compounds |
| MXPA06005910A (en) | 2003-11-25 | 2006-08-23 | 3M Innovative Properties Co | Substituted imidazo ring systems and methods. |
| JP2007513165A (en) * | 2003-12-02 | 2007-05-24 | スリーエム イノベイティブ プロパティズ カンパニー | Concomitant drugs containing IRM compounds and methods of treatment |
| WO2005066170A1 (en) | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
| JP2007517044A (en) | 2003-12-30 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinylsulfonamide |
| US8697873B2 (en) | 2004-03-24 | 2014-04-15 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| WO2005123080A2 (en) | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
| US8541438B2 (en) | 2004-06-18 | 2013-09-24 | 3M Innovative Properties Company | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
| US7897609B2 (en) | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
| US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
| US7915281B2 (en) | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
| US7943609B2 (en) | 2004-12-30 | 2011-05-17 | 3M Innovative Proprerties Company | Chiral fused [1,2]imidazo[4,5-C] ring compounds |
| WO2006074045A2 (en) * | 2004-12-30 | 2006-07-13 | 3M Innovative Properties Company | Immune response modifier formulations and methods |
| CA2594674C (en) | 2004-12-30 | 2016-05-17 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
| EP1844201B1 (en) | 2005-02-04 | 2016-08-24 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
| ES2475728T3 (en) | 2005-02-09 | 2014-07-11 | 3M Innovative Properties Company | Thiazoloquinolines and alkoxy substituted thiazolonaphthyridines |
| US7968563B2 (en) | 2005-02-11 | 2011-06-28 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
| AU2006232377A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
| AU2006232375A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
| ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
| EP1922317A4 (en) * | 2005-09-09 | 2009-04-15 | Coley Pharm Group Inc | Amide and carbamate derivatives of n-{2-ý4-amino-2- (ethoxymethyl)-1h-imidazoý4,5-c¨quinolin-1-yl¨-1,1-dimethylethyl}methanesulfonamide and methods |
| CA2623541A1 (en) * | 2005-09-23 | 2007-03-29 | Coley Pharmaceutical Group, Inc. | Method for 1h-imidazo[4,5-c]pyridines and analogs thereof |
| EP1988896A4 (en) | 2006-02-22 | 2011-07-27 | 3M Innovative Properties Co | Immune response modifier conjugates |
| WO2008008432A2 (en) | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
| CA2719544C (en) | 2008-03-24 | 2018-01-09 | 4Sc Ag | Substituted imidazoquinolines |
| PT2606047T (en) | 2010-08-17 | 2017-04-07 | 3M Innovative Properties Co | Lipidated immune response modifier compound compositions, formulations, and methods |
| EP2718292B1 (en) | 2011-06-03 | 2018-03-14 | 3M Innovative Properties Company | Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom |
| CN103582496B (en) | 2011-06-03 | 2016-05-11 | 3M创新有限公司 | There is the Heterobifunctional connection base of polyethylene glycol segment and the immune response modifier conjugate of being made by it |
| ES2663622T3 (en) | 2013-12-17 | 2018-04-16 | Pfizer Inc. | Novel 1-pyrrolo [2,3-b] 3,4-disubstituted pyridines and 7H-4,5-disubstituted pyridacins [2,3-c] pyridazines as inhibitors of LRRK2 |
| MX377305B (en) | 2015-09-14 | 2025-03-07 | Pfizer | NOVEL IMIDAZO[4,5-c]QUINOLINE AND IMIDAZO[4,5-c][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS. |
| ES2990113T3 (en) | 2016-07-07 | 2024-11-28 | The Board Of Trustees Of The Leland Stanfordjunior Univ | Antibody adjuvant conjugates |
| BR112019018688A2 (en) | 2017-03-10 | 2020-04-07 | Pfizer | imidazo [4,5-c] quinoline derivatives as lrrk2 inhibitors |
| US11279684B2 (en) | 2017-09-06 | 2022-03-22 | Bointech SE | Substituted imidazoquinolines as agonists of TLR7 |
| WO2019123178A1 (en) | 2017-12-20 | 2019-06-27 | 3M Innovative Properties Company | Amide substitued imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| KR20220119085A (en) * | 2019-12-20 | 2022-08-26 | 남미 테라퓨틱스, 인크. | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful for the treatment of cancer and methods thereof and methods thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH31245A (en) * | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives. |
| US6069149A (en) * | 1997-01-09 | 2000-05-30 | Terumo Kabushiki Kaisha | Amide derivatives and intermediates for the synthesis thereof |
| IL124914A (en) * | 1997-06-26 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical compositions containing 6-aryl-2,3,5,6-tetrahydroimidazo¬2,1-a¾isoquinoline derivatives and some new such compounds |
| JP2000119271A (en) * | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1H-imidazopyridine derivative |
| ES2229790T3 (en) * | 1998-10-26 | 2005-04-16 | The Research Foundation Of State University Of New York | DERIVATIVES OF LIPOIC ACID AND ITS USE FOR THE TREATMENT OF DISEASES. |
| US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| AU2002343728A1 (en) * | 2001-11-16 | 2003-06-10 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor pathways |
| US6677349B1 (en) * | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
-
2004
- 2004-06-24 MY MYPI20042461A patent/MY157827A/en unknown
- 2004-06-25 CA CA002529322A patent/CA2529322A1/en not_active Abandoned
- 2004-06-25 AR ARP040102248A patent/AR044923A1/en unknown
- 2004-06-25 BR BRPI0411916-9A patent/BRPI0411916A/en not_active IP Right Cessation
- 2004-06-25 WO PCT/US2004/020606 patent/WO2005003064A2/en not_active Ceased
- 2004-06-25 EP EP04756208A patent/EP1638566A4/en not_active Withdrawn
- 2004-06-25 MX MXPA06000144A patent/MXPA06000144A/en unknown
- 2004-06-25 AR ARP040102247A patent/AR044922A1/en unknown
- 2004-06-25 TW TW093118635A patent/TW200514784A/en unknown
- 2004-06-25 TW TW093118636A patent/TW200511992A/en unknown
- 2004-06-25 CN CN2004800181459A patent/CN1812789B/en not_active Expired - Fee Related
- 2004-06-25 WO PCT/US2004/020607 patent/WO2005003065A2/en not_active Ceased
- 2004-06-25 RU RU2005138915/04A patent/RU2374246C2/en not_active IP Right Cessation
- 2004-06-25 KR KR1020057024904A patent/KR20060035637A/en not_active Ceased
- 2004-06-25 AU AU2004253929A patent/AU2004253929A1/en not_active Abandoned
- 2004-06-25 NZ NZ544330A patent/NZ544330A/en unknown
- 2004-06-25 JP JP2006517711A patent/JP2007521280A/en active Pending
-
2005
- 2005-12-07 IL IL172427A patent/IL172427A0/en unknown
-
2006
- 2006-01-26 ZA ZA200600769A patent/ZA200600769B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005003065A2 (en) | 2005-01-13 |
| TW200511992A (en) | 2005-04-01 |
| WO2005003064A2 (en) | 2005-01-13 |
| MY157827A (en) | 2016-07-29 |
| JP2007521280A (en) | 2007-08-02 |
| IL172427A0 (en) | 2006-04-10 |
| CN1812789B (en) | 2010-07-14 |
| CN1812789A (en) | 2006-08-02 |
| WO2005003064A3 (en) | 2005-03-31 |
| MXPA06000144A (en) | 2006-04-07 |
| EP1638566A4 (en) | 2009-03-25 |
| NZ544330A (en) | 2009-06-26 |
| KR20060035637A (en) | 2006-04-26 |
| AR044923A1 (en) | 2005-10-12 |
| RU2374246C2 (en) | 2009-11-27 |
| ZA200600769B (en) | 2007-05-30 |
| RU2005138915A (en) | 2006-06-27 |
| BRPI0411916A (en) | 2006-08-15 |
| WO2005003065A3 (en) | 2005-03-10 |
| TW200514784A (en) | 2005-05-01 |
| CA2529322A1 (en) | 2005-01-13 |
| AR044922A1 (en) | 2005-10-12 |
| EP1638566A2 (en) | 2006-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004253929A1 (en) | Sulfonamide substituted imidazoquinolines | |
| US6677349B1 (en) | Sulfonamide and sulfamide substituted imidazoquinolines | |
| KR100781428B1 (en) | Sulfonamide and sulfamide substituted imidazoquinolines | |
| AU2002232482B2 (en) | Amido ether substituted imidazoquinolines | |
| US6969722B2 (en) | Amide substituted imidazopyridines | |
| AU766565B2 (en) | Urea substituted imidazoquinolines | |
| US6903113B2 (en) | Urea substituted imidazopyridines | |
| AU2002312414B2 (en) | Sulfonamido substituted imidazopyridines | |
| AU2002239547B2 (en) | Substituted imidazopyridines | |
| AU2002232497A1 (en) | Urea substituted imidazoquinoline ethers | |
| EP1642580A1 (en) | Sulfonamide substituted imidazoquinolines | |
| HK1088836A (en) | Sulfonamide substituted imidazoquinolines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |